<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">16228</article-id><article-id pub-id-type="doi">10.7554/eLife.16228</article-id><article-categories><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology</subject></subj-group><subj-group subj-group-type="display-channel"><subject>Tools and Resources</subject></subj-group></article-categories><title-group><article-title>NaLi-H1: A universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-54326"><name><surname>Moutel</surname><given-names>Sandrine</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-54327"><name><surname>Bery</surname><given-names>Nicolas</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2643-3897</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="equal-contrib">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-54328"><name><surname>Bernard</surname><given-names>Virginie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-54329"><name><surname>Keller</surname><given-names>Laura</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1786-9760</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-61963"><name><surname>Lemesre</surname><given-names>Emilie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-54330"><name><surname>de Marco</surname><given-names>Ario</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7729-819X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-54331"><name><surname>Ligat</surname><given-names>Laetitia</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-54332"><name><surname>Rain</surname><given-names>Jean-Christophe</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-54333"><name><surname>Favre</surname><given-names>Gilles</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2344-1883</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-54334"><name><surname>Olichon</surname><given-names>Aurélien</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" corresp="yes" id="author-9885"><name><surname>Perez</surname><given-names>Franck</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9129-9401</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="other" rid="par-6"/><xref ref-type="other" rid="par-7"/><xref ref-type="other" rid="par-8"/><xref ref-type="other" rid="par-9"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf5"/></contrib><aff id="aff1"><label>1</label><institution>Institut Curie, PSL Research University</institution>, <addr-line><named-content content-type="city">Paris</named-content></addr-line>, <country>France</country></aff><aff id="aff2"><label>2</label><institution>CNRS UMR144</institution>, <addr-line><named-content content-type="city">Paris</named-content></addr-line>, <country>France</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Translational Research Department</institution>, <institution>Institut Curie</institution>, <addr-line><named-content content-type="city">Paris</named-content></addr-line>, <country>France</country></aff><aff id="aff4"><label>4</label><institution>Inserm, UMR 1037-CRCT</institution>, <addr-line><named-content content-type="city">Toulouse</named-content></addr-line>, <country>France</country></aff><aff id="aff5"><label>5</label><institution>Faculté des Sciences Pharmaceutiques, Université Toulouse III-Paul Sabatier</institution>, <addr-line><named-content content-type="city">Toulouse</named-content></addr-line>, <country>France</country></aff><aff id="aff6"><label>6</label><institution>Institut Claudius Regaud</institution>, <addr-line><named-content content-type="city">Toulouse</named-content></addr-line>, <country>France</country></aff><aff id="aff7"><label>7</label><institution>Le Pôle Technologique du Centre de Recherches en Cancérologie de Toulouse, plateau de protéomique</institution>, <addr-line><named-content content-type="city">Toulouse</named-content></addr-line>, <country>France</country></aff><aff id="aff8"><label>8</label><institution>Hybrigenics Service</institution>, <addr-line><named-content content-type="city">Paris</named-content></addr-line>, <country>France</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Akhmanova</surname><given-names>Anna</given-names></name><role>Reviewing editor</role><aff id="aff9"><institution>Utrecht University</institution>, <country>Netherlands</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><email>aurelien.olichon@inserm.fr</email> (AO);</corresp><corresp id="cor2"><email>Franck.Perez@curie.fr</email> (FP)</corresp><fn fn-type="con" id="equal-contrib"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="pub" publication-format="electronic"><day>19</day><month>07</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>5</volume><elocation-id>e16228</elocation-id><history><date date-type="received"><day>20</day><month>03</month><year>2016</year></date><date date-type="accepted"><day>18</day><month>07</month><year>2016</year></date></history><permissions><copyright-statement>© 2016, Moutel et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Moutel et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-16228-v2.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.16228.001</object-id><p>In vitro selection of antibodies allows to obtain highly functional binders, rapidly and at lower cost. Here, we describe the first fully synthetic phage display library of humanized llama single domain antibody (NaLi-H1: Nanobody Library Humanized 1). Based on a humanized synthetic single domain antibody (hs2dAb) scaffold optimized for intracellular stability, the highly diverse library provides high affinity binders without animal immunization. NaLi-H1 was screened following several selection schemes against various targets (Fluorescent proteins, actin, tubulin, p53, HP1). Conformation antibodies against active RHO GTPase were also obtained. Selected hs2dAb were used in various immunoassays and were often found to be functional intrabodies, enabling tracking or inhibition of endogenous targets. Functionalization of intrabodies allowed specific protein knockdown in living cells. Finally, direct selection against the surface of tumor cells produced hs2dAb directed against tumor-specific antigens further highlighting the potential use of this library for therapeutic applications.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16228.001">http://dx.doi.org/10.7554/eLife.16228.001</ext-link></p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.16228.002</object-id><title>eLife digest</title><p>Antibodies are proteins that form part of an animal’s immune system and can identify and help eradicate infections. These proteins are also needed at many stages in biological research and represent one of the most promising tools in medical applications, from diagnostics to treatments.</p><p>Traditionally, antibodies have been collected from animals that had been previously injected with a target molecule that the antibodies must recognize. An alternative strategy that uses bacteria and bacteria-infecting viruses instead of animals was developed several decades ago and allows researchers to obtain antibodies more quickly. However, the majority of the scientific community view these “in vitro selected antibodies” as inferior to those produced via the more traditional approach.</p><p>Moutel, Bery et al. set out to challenge this widespread opinion, using a smaller kind of antibody known as nanobodies. The proteins were originally found in animals like llamas and camels and are now widely used in biological research. One particularly stable nanobody was chosen to form the backbone of the in vitro antibodies, and the DNA that encodes this nanobody was altered to make the protein more similar to human antibodies. Moutel, Bery et al. then changed the DNA sequence further to make billions of different versions of the nanobody, each one slightly different from the next in the region that binds to the target molecules.</p><p>Transferring this DNA into bacteria resulted in a library (called the NaLi-H1 library) of bacterial clones that produce the nanobodies displayed at the surface of bacteria-infecting viruses. Moutel, Bery et al. then screened this library against various target molecules, including some from tumor cells, and showed that the fully in vitro selected antibodies worked just as well as natural antibodies in a number of assays. The in vitro antibodies could even be used to track, or inactivate, proteins within living cells.</p><p>The NaLi-H1 library will help other researchers obtain new antibodies that bind strongly to their targets. The approaches developed to create the library could also see more people decide to create their own synthetic libraries, which would accelerate the identification of new antibodies in a way that is cheaper and requires fewer experiments to be done using animals. These in vitro selected antibodies could help to advance both fundamental and medical research.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16228.002">http://dx.doi.org/10.7554/eLife.16228.002</ext-link></p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author Keywords</title><kwd>recombinant antibodies</kwd><kwd>phage display</kwd><kwd>intrabodies</kwd><kwd>synthetic library</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research Organism</title><kwd><italic>E. coli</italic></kwd><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001665</institution-id><institution>Agence Nationale de la Recherche</institution></institution-wrap></funding-source><award-id>ANR-09-BIOT-05</award-id><principal-award-recipient><name><surname>Rain</surname><given-names>Jean-Christophe</given-names></name><name><surname>Perez</surname><given-names>Franck</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001677</institution-id><institution>Institut National de la Santé et de la Recherche Médicale</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Favre</surname><given-names>Gilles</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution>Groupe de Recherche of the Claudius Regaud Institute</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Favre</surname><given-names>Gilles</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001677</institution-id><institution>Institut National de la Santé et de la Recherche Médicale</institution></institution-wrap></funding-source><award-id>ITS-201103</award-id><principal-award-recipient><name><surname>Perez</surname><given-names>Franck</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution>IDEX Paris Sciences Lettres</institution></institution-wrap></funding-source><award-id>ANR-10-IDEX-0001-02 PSL</award-id><principal-award-recipient><name><surname>Perez</surname><given-names>Franck</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution>LABEX CellTisPhyBio</institution></institution-wrap></funding-source><award-id>11-LBX-0038</award-id><principal-award-recipient><name><surname>Perez</surname><given-names>Franck</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004794</institution-id><institution>Centre National de la Recherche Scientifique</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Perez</surname><given-names>Franck</given-names></name></principal-award-recipient></award-group><award-group id="par-8"><funding-source><institution-wrap><institution>Institut Curie</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Perez</surname><given-names>Franck</given-names></name></principal-award-recipient></award-group><award-group id="par-9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002915</institution-id><institution>Fondation pour la Recherche Médicale</institution></institution-wrap></funding-source><award-id>DEQ20120323723</award-id><principal-award-recipient><name><surname>Perez</surname><given-names>Franck</given-names></name></principal-award-recipient></award-group><award-group id="par-10"><funding-source><institution-wrap><institution>Aviesan</institution></institution-wrap></funding-source><award-id>Project TAbIP</award-id><principal-award-recipient><name><surname>Perez</surname><given-names>Franck</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2.5</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A fully synthetic library of humanized single domain antibodies yields in vitro high affinity antibodies usable in cell biology and translational projects.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Antibodies expended as the biochemical tools of choice to label antigens in cells or tissues. Over the past 20 years, recombinant methods have been developed to quickly select and improve monoclonal antibodies from highly diverse libraries. Recombinant antibodies can be selected from immune or naïve libraries. Immune libraries provide in general high affinity binders but, depending on the antigen, diversity is sometimes limited. Because natural antibody selection requires animal immunization, very conserved or toxic antigens should be avoided and, in general, only limited control of the immune response is possible. On the contrary, non-immune (naïve) libraries provide a higher diversity of binders even for antigens highly conserved in mammals, but high specificity and affinity can be reached only when selecting from very large functional libraries. Immune and naïve libraries are based on the manipulation of antibody fragment that retain binding capacity and specificity of the entire immunoglobulin G (IgG).</p><p>The smallest IgG portion capable of binding with high specificity an antigen is the Fv fragment consisting of the variable heavy (VH) and the variable light (VL) domains. In the case of single domain antibodies (sdAb), a VH or a VL alone, is able to bind its target antigen. Each variable domain contains four conserved framework regions (FRW or framework) and three regions called CDR (Complementarity Determining Regions) corresponding to hypervariable sequences which determine the specificity for the antigen. VH and VL can be fused together using a synthetic linker and produced as a single protein in the form of a single chain Fv (scFv). Easier to manipulate, they can be produced in several bacteria or eukaryote cell types, fused to various tags or functional domains. Interestingly, antibodies called HCAb in <italic>Camelidae</italic> (<xref ref-type="bibr" rid="bib14">Hamers-Casterman et al., 1993</xref>) or IgNAR in sharks (<xref ref-type="bibr" rid="bib12">Greenberg et al., 1995</xref>) have an antigen recognition part composed of only a VH domain. Camelid natural single domain VH, referred to as VHH or nanobodies, can be expressed as recombinant fragments and represent attractive alternatives over classical antibody fragments like scFvs because they are easy to manipulate and they are not limited by potential misfolding of the two domains (<xref ref-type="bibr" rid="bib56">Wörn and Plückthun, 1999</xref>). It is noteworthy that VHH FRWs show a high sequence and structural homology with human VH domains of family III (<xref ref-type="bibr" rid="bib33">Muyldermans, 2013</xref>) and VHH have comparable immunogenicity as human VH (<xref ref-type="bibr" rid="bib1">Bartunek et al., 2013</xref>; <xref ref-type="bibr" rid="bib16">Holz et al., 2013</xref>). Thus, they further constitute very interesting agents for therapeutic applications, some of them are currently in phase II and Phase III clinical trials (Ablynx Nanobodies; <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/results?term=ablynx">http://clinicaltrials.gov/ct2/results?term=ablynx</ext-link>).</p><p>Recombinant antibody fragments allowed not only to accelerate the identification of unique binders, but also the development of a novel type of tool: in this case, the antibodies are directly expressed in living cells as intracellular antibodies (intrabodies), to trace or perturb endogenous target at the protein level. Some scFv or sdAb have indeed been directly expressed in eukaryotic cell as intrabodies to target with high specificity intracellular antigens. Several intrabodies have been used as fluorescent protein fusion to highlight endogenous antigen in cells in a spatio-temporal manner (<xref ref-type="bibr" rid="bib34">Nizak et al., 2003a</xref>; <xref ref-type="bibr" rid="bib44">Rothbauer et al., 2006</xref>). Intrabodies with intrinsic blocking activity have been reported (<xref ref-type="bibr" rid="bib15">Haque et al., 2011</xref>; <xref ref-type="bibr" rid="bib46">Shin et al., 2005</xref>), and several other approaches have been developed to allow a larger fraction of intrabodies to be used as inhibitory factors: forced co-localization (<xref ref-type="bibr" rid="bib50">Tanaka et al., 2007</xref>), suicide through proteasome targeting (<xref ref-type="bibr" rid="bib19">Joshi et al., 2012</xref>; <xref ref-type="bibr" rid="bib29">Melchionna and Cattaneo, 2007</xref>), rerouting or sequestration to cell compartment (<xref ref-type="bibr" rid="bib3">Böldicke et al., 2005</xref>), degradation (<xref ref-type="bibr" rid="bib4">Caussinus et al., 2011</xref>). Depending on the target, such inhibitors may have potential in human therapy. Production of functional intrabodies depends on the stability of the antibody fragments in the reducing environment of the cytosol that does not allow disulfide bond formation between conserved cysteine. In this context, many advantages of the nanobody scaffold have been reported and, in particular, higher solubility, improved stability in a reducing environment (<xref ref-type="bibr" rid="bib55">Wesolowski et al., 2009</xref>), as well as higher expression yield and thermostability (<xref ref-type="bibr" rid="bib18">Jobling et al., 2003</xref>). For all these reasons, the nanobody scaffold represents an attractive option to generate functional intrabodies.</p><p>Thus, we decided to create a non-immune recombinant antibody library of high diversity, based on a nanobody scaffold that would enable efficient in vitro antibody selection against virtually any antigen. Such a library should provide antibodies usable in conventional immune assays and be enriched in antibodies active in the intracellular environment. First, using a fusion assay in <italic>E. coli</italic>, a family of highly functional VHH scaffolds was isolated, optimized for intracellular expression and high stability. One particularly stable VHH scaffold consensus sequence was chosen from these selected antibodies. Additional changes were then introduced to reduce the distance between the <italic>Camelidae</italic> and human VH3 sequences. We confirmed by CDR grafting that this humanized synthetic scaffold (hs2dAb) was robust and functional. Statistics of amino-acid diversity in the CDRs were computed and these information were used to construct a high diversity phage display library of 3.10<sup>9</sup> independent hs2dAb. The library was then screened against diverse targets of various structures and origin. Highly specific antibodies were selected against EGFP, mCherry, β-tubulin, β-actin, heterochromatin protein HP1α, GTP-bound RHO, p53 and HER2. Affinity measurement indicated that affinities in the nM range can be obtained using this library. As expected from our design, we further showed that hs2dAb are frequently usable as fluorescent intrabodies to track antigens in cells. We also showed that they can be functionalized to induce antigen knockdown. This thus represents the first report of a large and diverse synthetic single domain antibody library enabling fully in vitro selection of highly functional antibodies and intrabodies.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Library design</title><p>We reasoned that the usual lower quality of these non-immune libraries may come from (1) an antibody scaffold that may not allow robust folding and presentation of CDR region, (2) a lack of control of diversity in the CDR regions and (3) a frequent occurrence of incorrect clones due to the presence of unexpected mutation or empty clones. We designed a pipeline for the development of functional synthetic libraries that aims at overcoming these limitations (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). As a first step to construct a single domain antibody library enriched in highly stable and functional antibody fragments, we screened for a robust sdAb scaffold (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Previously, we selected from immune or naïve llama VHH libraries several hundreds of clones (<xref ref-type="bibr" rid="bib31">Monegal et al., 2012</xref>; <xref ref-type="bibr" rid="bib37">Olichon and Surrey, 2007</xref>). From this population, we identified a set of robust scaffolds using an assay that discriminates highly stable clones from clones prone to aggregation, or unfolding, in the bacterial cytoplasm (<xref ref-type="bibr" rid="bib37">Olichon and Surrey, 2007</xref>). This assay is based on the fusion of HA-tagged chloramphenicol acetyl transferase (CAT) to the carboxy-terminus of VHH sequences (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). In these conditions, only bacteria expressing a functional VHH fusion in the reducing cytosol (non aggregating, non degraded) can grow in the presence of high antibiotic concentration, thus filtrating a sub-library of potential intrabodies. Expression yield in <italic>E.coli</italic> and apparent solubility as EGFP fusion in the mammalian cell cytoplasm were further assessed to select a set of robust antibody scaffolds. Strikingly, the consensus scaffold was matching the sequence of the most robust VHH framework, represented by a single domain antibody D10 (hereafter named sdAb<sup>D10</sup>). When compared to previously reported thermostable nanobodies (<xref ref-type="bibr" rid="bib38">Olichon et al., 2007a</xref>) or intrabodies (<xref ref-type="bibr" rid="bib44">Rothbauer et al., 2006</xref>) obtained from immune libraries, sdAb<sup>D10</sup> was found to provide higher antibiotic resistance in the chloramphenicol filter assay (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). Its expression yield in <italic>E.coli</italic> periplasm was in the higher range of soluble llama VHH fragments, allowing efficient and quantitative purification (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). Purified sdAb<sup>D10</sup> showed excellent solubility, stability after treatment at 70°C and we did not observe aggregation when expressed as an intrabody fused to the EGFP in mammalian cells (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>).<fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.16228.003</object-id><label>Figure 1.</label><caption><title>Overview of scaffold selection, diversity design, and synthetic production of the NaLi-H1 library.</title><p>The development of the NaLi-H1 library followed three lines of optimization. (i) A novel scaffold was defined by selecting a set of robust nanobodies using a CAT fusion assay (1). A consensus was derived and mutations were introduced to humanize the scaffold (2). Usability and efficacy of the novel scaffolds (VHH and humanized) were then confirmed evaluating their display on phage, expression in CHO cells and use as intrabodies (3).In silico design was completed analyzing natural CDR diversity (4) and using this information to design synthetic CDRs. A fixed size of 7 aa was chosen for the CDR1 and CDR2. 4 sizes (9, 12, 15 and 18 amino acids) were chosen for CDR3. Finally, the pHEN2 vector was improved by implementing a triple myc tag and inserting a toxic gene (ccdb) to ensure low frequency of empty clones during library construction (6). Gene synthesis (using a tri-nucleotide approach) was ordered, synthetic sequences cloned into the novel pHEN2+ vector, transformed into bacteria and plated on 430 15 cm plates. 3 × 10<sup>9</sup> clones were obtained. Quality control was carried out using Sanger sequencing of 315 randomly picked clones and large scale sequencing of 56 000 clones. No redundant clone was found. The NaLi-H1 was then screened in various conditions and diversity, efficacy, versatility and affinity evaluated.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16228.003">http://dx.doi.org/10.7554/eLife.16228.003</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-16228-fig1-v2"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.16228.004</object-id><label>Figure 1—figure supplement 1.</label><caption><title>Robust scaffold identification.</title><p>(<bold>A</bold>) Chloramphenicol acetyl transferase carboxy terminal fusion is a folding reporter allowing for the selection of soluble amino terminal VHH. Top: scheme of the construct expressed from pAO-VHH-CAT-HA vector. Bottom: Relative colony growth of selected VHH (GFP4 and Lam1 chromobodies, or thermostable Re3) on chloramphenicol selection medium (Cam). Serial dilution of <italic>E.coli</italic> culture expressing VHH. (<bold>B</bold>) Analysis of heat purified sdAb<sup>D10</sup> by SDS-PAGE. Clone D10 was expressed in <italic>E.coli</italic> and protein secreted in the periplasm were extracted (lane 1). Periplasmic extract was subjected to heat treatment at 70°C and insoluble proteins were pelleted by centrifugation (lane 2). The soluble supernatant containing the VHH was then concentrated using Amicon filters (lane 3). (<bold>C</bold>) HeLa cells expressing a GFP fusion of sdAb<sup>D10</sup> showing homo-dispersed fluorescence (right) compared to typical randomly chosen aggregating llama VHH considered as non intrabody (left).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16228.004">http://dx.doi.org/10.7554/eLife.16228.004</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-16228-fig1-figsupp1-v2"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.16228.005</object-id><label>Figure 1—figure supplement 2.</label><caption><title>CDR3 loop grafting and synthetic scaffold validation.</title><p>(<bold>A</bold>) Phages presenting each scaffolds (sdAbD<sup>10</sup> and hs2dAb) bearing anti-lamin CDRs were produced in <italic>E.coli</italic> and supernatant were detected in Western Blot with an anti-pIII antibody (NEB). Two bands are visible, one for wild-type pIII and one for the pIII fusion with single domain antibodies. (<bold>B</bold>) Dot blot analysis of the production of both scaffolds either as single domain antibodies in <italic>E. coli</italic> supernatant or as fusions with a human Fc domain and secreted by CHO cells (<xref ref-type="bibr" rid="bib32">Moutel et al., 2009</xref>). Serial dilutions of supernatant were revealed with an anti-His tag antibody or an anti-human Fc antibody. (<bold>C</bold>) Immunofluorescence of HeLa cells with recombinant antibody in both scaffolds labeling the nuclear rim structure characteristic of the nuclear lamina. (<bold>D</bold>) The anti-lamin based on the two scaffolds were transiently expressed in HeLa cells as GFP fusion. Living cells were imaged after 24 hr and showed that the hs2dAb recognized its intracellular target lamin. Bar = 10 µm.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16228.005">http://dx.doi.org/10.7554/eLife.16228.005</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-16228-fig1-figsupp2-v2"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.16228.006</object-id><label>Figure 1—figure supplement 3.</label><caption><title>Nali-H1 library diversity.</title><p>(<bold>A</bold>) Comparison between relative amino acid frequencies in CRD1 and CDR2 observed from 250 llama VHH isolated from a naïve library (llama), the rationally designed (Designed) and the effective diversity in the synthetic library (Nali-H1) as computed after sequencing of 2500 clones using NGS. The position of each amino acid is indicated (CDR1 1; CDR1 2; etc). Amino Acid are indicated in single letter code. (<bold>B</bold>) Comparison between the designed diversity set for every amino acid position in the CDR3 region with the effective diversity observed after sequencing 2500 clones using NGS. Note that various CDR3 amino acid lengths are present in the library. They were almost evenly distributed with a little bias for shorter CDR3s (9 aa: 26%; 12 aa: 27.2%; 15 aa: 23.7%; 18 aa: 23.1%). For simplicity, we report in the figure the diversity observed for up to 18 aa. Note also that although cysteine occurs in natural llama CDRs, they were avoided by design and, accordingly, not found in Nali-H1 CDRs.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16228.006">http://dx.doi.org/10.7554/eLife.16228.006</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-16228-fig1-figsupp3-v2"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.16228.007</object-id><label>Figure 1—figure supplement 4.</label><caption><title>Solubility of secreted hs2dAb antibodies.</title><p>(<bold>A</bold>) Sequential centrifugation carried out using clones selected from the NaLi-H1 library (anti-GFP, anti-mCherry) or obtained after CDR grafting into the hs2dAb scaffold (anti-lamin). As a reference, the behaviour of a widely used natural anti-GFP antibody (GFP4 or Chromobody) was analysed. I: Input; P1: pellet after the 20 000 <italic>g</italic> centrifugation, P2: pellet obtained after the 250 000 <italic>g</italic> centrifugation, SN: supernatant of the 250 000 <italic>g</italic> centrifugation. Samples were analysed after western blotting using an anti-HIS antibody. Note that the apparent size of the lamin antibody and the Chromobody is lower because these antibodies are fused to only one myc tag (expressed from the parental pHEN2-His-Myc plasmid). (<bold>B</bold>), (<bold>C</bold>): a set of clones randomly chosen in the NaLi-H1 library was expressed in a multiwell format and analysed as in A. Only-the pellet (<bold>P</bold>) and the supernatant (SN) of the 250 000 <italic>g</italic> centrifugation are shown. Two samples (an anti-GFP hs2dAb and a randomly picked clone #1) were heated at 90°C for 10 min before being analysed by sequential centrifugation (anti-GFP* and #1*). Note that in these conditions, a fraction of the hs2dAb is unfolded and found in the pellet. A significant resistance to temperature is however observed. Note that high molecular weight bands were systematically seen which may suggest that a fraction of the hs2dAb is in a multimeric form. The same behaviour was observed for the natural Chromobody.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16228.007">http://dx.doi.org/10.7554/eLife.16228.007</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-16228-fig1-figsupp4-v2"/></fig></fig-group></p><p>To test whether the sdAb<sup>D10</sup> scaffold composed of the FRW 1 to 4 was robust independently on the CDR sequences, we grafted the CDR loops of the lam1 VHH (<xref ref-type="bibr" rid="bib44">Rothbauer et al., 2006</xref>) directed against laminB into the framework of the sdAb<sup>D10</sup> (<italic>sdAb<sup>D10</sup>-anti lamin).</italic> In parallel, partial humanization of the scaffold was also tested to figure out whether it affected dramatically its intrinsic properties. Seven residues of the synthetic scaffold sdAb<sup>D10</sup> were altered towards the most represented in human VH3 while five other divergent residues were kept unchanged. The four llama VHH-specific amino acids hallmarks in the framework-2 region (positions 42, 49, 50, and 52), which are essential to increase intrinsic solubility properties, as well as the Glutamine in position 103, were maintained. We named the resulting hybrid single domain VH hs2dAb (<italic>humanized synthetic single domain antibody</italic>) (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). After grafting the CDR of the anti-lamin into these two scaffolds, we analyzed their display on the M13 surface (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>) and their production by <italic>E. coli</italic> and by CHO cells (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>). Both scaffold showed similarly good efficacy. Importantly, both the sdAb<sup>D10</sup> and hs2dAb scaffolds enabled functional display of the grafted CDRs and robust detection of endogenous lamin was observed by immunofluorescence staining of Hela cells (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>). Last, Rothbauer et al. (<xref ref-type="bibr" rid="bib44">Rothbauer et al., 2006</xref>) showed that the original anti-lamin VHH recognized its target antigen upon intracellular expression. Similarly, we observed that both the hs2dAb and the sdAb<sup>D10</sup> scaffolds allowed the efficient intrabody use of the synthetic anti-lamin antibodies (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2D</xref>). This further indicated that the synthetic scaffolds were robust, non-aggregating and resisted to the reducing conditions found in the cytosol, while allowing the proper display of CDR loops. As partial humanization did not affect the properties of the sdAb<sup>D10</sup> scaffold, we chose the hs2dAb scaffold as a unique framework to construct a diverse library of synthetic nanobodies endowed with the characteristic stability of these single domain antibodies while displaying an amino acid sequence closer to human VH3.</p></sec><sec id="s2-2"><title>Library construction</title><p>A synthetic diversity was introduced in the three CDRs by rationally controlling each position of the CDR1 and CDR2 using a set of amino acids that recapitulates partially natural diversity (see the Appendix for more details) while reducing the presence of the most hydrophobic residues in order to avoid the aggregation propensity (see Material and methods). A constant length of 7 amino acids was selected for CDR1 and CDR2. A large spectrum of <italic>Camelidae</italic> VHH CDR3 length is naturally observed and this loop is known to contribute strongly to antigen binding selectivity. Thus, we chose to use four different lengths of CDR3 to cover this spectrum (9, 12, 15 or and 18 amino acids) and introduce random amino acid (except cysteine) at each position.</p><p>Synthetic DNA was produced by the trinucleotide DNA assembly and amplification was carried out starting from 2.10<sup>11</sup> different molecules, using only a few cycles of PCR (PCR linearity validated by Q-PCR) to prevent drift during amplification. The synthetic library was inserted into a modified pHEN2 phagemid vector containing a triple myc-tag and suicide gene (ccdB) that allowed positive selection of insert-bearing clones (<xref ref-type="bibr" rid="bib2">Bernard et al., 1994</xref>). Massive electroporation was carried out using <italic>E. coli</italic> TG1 cells and 430 large agar dishes (140 mm) were used to ensure proper plating of the library. About 3.10<sup>9</sup> individual recombinant hs2dAb clones were obtained. We named this library NaLi-H1 (for Nanobody Library-Humanized 1). We first evaluated the quality of the NaLi-H1 library by sequencing 315 random clones. Only 13 sequences were found to be incorrect (bearing an in-frame stop codon, missing one base, missing a large region [the CDR1 or CDR1-FWR1- CDR2], or being empty). Thus, a total of about 4% of potential default was observed, which is rather low and only marginal in comparison to the 3.10<sup>9</sup> clones obtained. The diversity was then evaluated by sequencing 5.6 10<sup>5</sup> inserts using ion Torrent chips (Life Technologies). This confirmed the quality of the library and showed that the four CDR3 lengths (9, 12, 15 or and 18 amino acids) were present in similar proportions. The diversity and statistical distribution of amino acids in the CDRs were found to be as expected (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). To estimate the overall folding of the hs2dAb present in the library, we picked randomly 24 clones and tested their solubility in bacteria medium after secretion. Medium were centrifuged at 250 000 <italic>g</italic> and the supernatant and pellet were analyzed. All tested clones showed essentially complete solubility, at least as good as a natural Lama antibody (GFP4). Even after warming at 90°C for 10 min, the hs2dAb showed good solubility (over 70%) (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>).</p></sec><sec id="s2-3"><title>Library screening and validation</title><p>The NaLi-H1 library was screened against a set of various antigens. Several standard phage display methods (<xref ref-type="bibr" rid="bib17">Hoogenboom, 2005</xref>) were used (see Materials and methods for details): antigen adsorption on immunotube, native antigen captured on beads, direct selection at the cell surface. All conditions allowed the efficient recovery of diverse and functional antibodies.</p><p>As a first screen to evaluate the quality of the library, we chose to select specific binders for the EGFP and mCherry fluorescent proteins. NaLi-H1 phages were panned against biotinylated EGFP or mCherry and 3 rounds of selection were carried out. Eighty clones were analyzed for each screening campaign. From the panning against EGFP, 37 non redundant nanobodies were shown to detect EGFP by phage ELISA. These antibodies were then used for immunofluorescence and 10 of them were found to efficiently stain EGFP in fixed HeLa cells (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Similarly, selection against mCherry led to 6 positive binders (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). As shown in <xref ref-type="fig" rid="fig2">Figure 2A and B</xref>, no staining was obtained in untransfected cells.<fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.16228.008</object-id><label>Figure 2.</label><caption><title>Selection of functional hs2dAb against various antigens.</title><p>(<bold>A</bold>) HeLa cells were transfected with GFP-Rab6, fixed using paraformaldehyde, permeabilized using saponin and stained with non-purified myc-tagged hs2dAb (R3TF3) directed against EGFP and revealed with anti-Myc-Tag (9E10) and Cy3-labeled secondary antibodies. (<bold>B</bold>) HeLa cells transfected with mCherry-Rab6, fixed and permeabilized as in A and stained using a myc-tagged non purified hs2dAb against mCherry (C11). The hs2dAb was then revealed using 9E10 and A488-labeled secondary antibodies. (<bold>C</bold>) Cells were fixed in methanol and co-stained with a non-purified anti-tubulin hs2dAb (D5) fused to a human Fc domain and a mouse monoclonal anti-tubulin antibody (DM1A), and revealed using an anti-Human Fc-A488 and an anti-Mouse-Cy3 secondary antibody, respectively. (<bold>D</bold>) hs2dAb F4 anti-beta-actin was used to stain MRC5 cells fixed with paraformaldehyde and post fixed with methanol. The hs2dAb was then revealed using 9E10 and A488-labeled secondary antibodies. Cells were co-stained by red fluorescent phalloidin to detect actin stress fibers. (<bold>E</bold>) A431 cells were fixed with 3% paraformaldehyde, permeabilized with 0.1% Triton and stained with the anti-p53 hs2dAb (B7) fused to a human Fc domain together with a rabbit polyclonal antibody directed against p53. Immuno-labeling was revealed using anti-Human Fc-Cy3 and anti-Rabbit-A488 secondary antibodies. (<bold>F</bold>) The hs2dAb antibody directed against HP1α (A5) fused to a human Fc domain was used to stain HeLa cells fixed with paraformaldehyde and permeabilized with 0.1% TritonX100. Cells were co-stained using a polyclonal rabbit antibody directed against HP1α and immuno-labeling was revealed using anti-Human Fc-Cy3 and anti-Rabbit-A488 secondary antibodies. (scale bar = 10 µm).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16228.008">http://dx.doi.org/10.7554/eLife.16228.008</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-16228-fig2-v2"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.16228.009</object-id><label>Figure 2—figure supplement 1.</label><caption><title>Specificity of hs2dAb directed against tubulin and actin.</title><p>(<bold>A</bold>) HeLa cells were left untreated (top) or incubated with 10 µM nocodazole for 90 min at 37°C (bottom). Cells were then permeabilized using 0.2% tritonX100, fixed using methanol (−20°C, 4 min) and immunolabelled using an anti-tubulin hs2dAb (green) and a polyclonal anti-tubulin antibody (Red). Staining was essentially lost upon nocodazole treatment with only few nocodazole-stable microtubules being labelled. Bar = 10 µm (<bold>B</bold>) HeLa cells were left untreated (top) or incubated with 5 µM cytochalasin D for 60 min at 37°C (bottom). Cells were then fixed using paraformaldehyde, permeabilized with saponin and immunolabelled using the anti-actin hs2dAb H2 (green) and a polyclonal anti-actin antibody (Red). Staining was strongly reorganized upon cytochalasin D treatment. Bar = 10 µm (<bold>C</bold>) SDS-PAGE of 40 µg sample per well of WI38 whole cell extract was blotted and separated in stripes for each lane. Stripes were then incubated for immuno-detection with various hs2dAb (lane 1–3: anti-actin hs2dAb; lane 4: non relevant [NR] control; lane 6: anti-tubulin hs2dAb) directly used from <italic>E.coli</italic> culture supernatant and further revealed using myc-HRP antibodies. Control monoclonal anti-actin or anti-tubulin were used on stripes 5 and 7, respectively.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16228.009">http://dx.doi.org/10.7554/eLife.16228.009</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-16228-fig2-figsupp1-v2"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.16228.010</object-id><label>Figure 2—figure supplement 2.</label><caption><title>Specificity of the anti-p53 hs2dAb.</title><p>(<bold>A</bold>) RPE-1 were left untreated or irradiated with UV light (100 J/m<sup>2</sup>). Cells were then fixed and stained using an anti-p53 hs2dAb together with an anti-p53 rabbit polyclonal antibody. Both the polyclonal and the hs2dAb antibodies detected the strong increase of p53 localization in the nuclei. (<bold>B</bold>) RPE-1 cells stably expressing an shRNA directed against p53 together with GFP were irradiated as in A and stained using the hs2dAb. No labeling was obtained in p53 KD cells. Bar = 10 µm.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16228.010">http://dx.doi.org/10.7554/eLife.16228.010</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-16228-fig2-figsupp2-v2"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.16228.011</object-id><label>Figure 2—figure supplement 3.</label><caption><title>Specificity of the anti-HP1 hs2dAb.</title><p>(<bold>B</bold>). (<bold>A</bold>) GFP tagged HP1α, HP1b and HP1γ were expressed in Hela cells. Cells were then lysed and extract separated by SDS-PAGE, transferred on nitrocellulose filters. Immunodetection was carried out using an anti-GFP antibody (left) or an anti-HP1 hs2dAb. Although the selection was carried out against was HP1α, the hs2dAb efficiently detected GFP tagged HP1α, HP1β and HP1γ. The band indicated by a star likely represent the endogenous HP1 proteins. (<bold>B</bold>) Cells were transfected as in (<bold>A</bold>), fixed and analyzed by immunofluorescence using the anti-HP1 hs2dAb. Nuclei were stained using DAPI. GFP tagged HP1α, HP1b and HP1γ were all efficiently detected by the recombinant antibody. Bar = 10 µm.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16228.011">http://dx.doi.org/10.7554/eLife.16228.011</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-16228-fig2-figsupp3-v2"/></fig></fig-group></p><p>In the next screen, two highly and constitutively expressed components of cell cytoskeleton, tubulin and β-actin, were targeted. Antibodies against tubulin were selected in native conditions (<xref ref-type="bibr" rid="bib34">Nizak et al., 2003a</xref>) using commercial biotinylated tubulin (Cytoskeleton). After two rounds of selection, 3 out of 40 clones analyzed were shown to detect endogenous tubulin by immunofluorescence (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). As expected, staining was lost in cells treated with the microtubule destabilizing drug nocodazole, with only a few stable microtubules being labelled in these conditions (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). This antibody was recently used to stain microtubules by super-resolution imaging (<xref ref-type="bibr" rid="bib30">Mikhaylova et al., 2015</xref>). Among phage display methods, selection on antigens directly adsorbed on the surface of immunotube is often used as a cheap and straightforward method, despite the low capacity and the strong denaturation imposed by non-specific adsorption. A screen against coated β-actin led to the identification of 16 unique binders positive in phage ELISA. Seven of these antibodies decorated endogenous actin stress fibers by immunofluorescence in MRC5 cells (<xref ref-type="fig" rid="fig2">Figure 2D</xref>) as well as in other cell lines. Treatment of cells with cytochalasin D disorganizes actin fibers. Accordingly, staining with the hs2dAb was strongly altered (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). Three of the hs2dAb detected a single band at the molecular weight of β-actin in western blot from HeLa cell extract while one of the anti-tubulin detected a band at the correct molecular weight of tubulin (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>).</p><p>Actin and tubulin are strongly expressed cellular proteins. Another screen was thus performed to select binders directed against proteins expressed at a lower level. A first screen was carried out against the tumor suppressor p53 protein. The 83 first amino acids of the NP_000537.3 isoform were produced in bacteria fused to a SNAP tag, biotinylated in vitro and used as a target in the phage display selection. Among 12 clones positive in phage ELISA, 6 selected hs2dAb were shown to label endogenous p53 in immunofluorescence on A431 cells (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). The specificity of the staining was confirmed using RPE-1 cells (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). A low nuclear staining was observed in normal conditions, with some variability between cells. As expected, the intensity was enhanced upon UV-induced DNA damage. Such an increase was not observed in a RPE-1 cell line stably expressing an shRNA against p53. A second screen was carried out against the heterochromatin protein HP1α. HP1α was produced in bacteria fused to an avitag to obtain a biotinylated recombinant protein. Biot-HP1α was then immobilized on streptavidin beads and used as a target for 3 rounds of selection. 5 individual hs2dAb were directly identified by immunofluorescence staining of HeLa cells. <xref ref-type="fig" rid="fig2">Figure 2F</xref> shows that selected antibodies were efficiently staining endogenous HP1 in the nucleus. Overexpression of the different HP1 variant followed by western blot and immunofluorescence analysis actually suggested that HP1β/γ were also detected by the antibody (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>). Together these results showed that the NaLi-H1 synthetic library can be screened in various conditions against very different purified targets while leading to the rapid identification of diverse and specific binders that can be used in classical antibody-based staining methods.</p></sec><sec id="s2-4"><title>Selection of conformation-sensitive antibodies</title><p>One of the main advantages of full in vitro immunization using display technologies is the control of antigen conformation and concentration. It allows to drive selection towards the desired outcome. For example, selection schemes can be devised to improve the recovery of high affinity binders endowed with low off-rate kinetics (<xref ref-type="bibr" rid="bib24">Lee et al., 2007</xref>), to target specific epitopes (<xref ref-type="bibr" rid="bib9">Even-Desrumeaux et al., 2014</xref>; <xref ref-type="bibr" rid="bib54">Vielemeyer et al., 2009</xref>), or to identify conformation sensitive-binders (<xref ref-type="bibr" rid="bib15">Haque et al., 2011</xref>). Recombinant antibody fragment library screening have, for example, provided several binders targeting selectively the active conformation of GTP binding proteins (<xref ref-type="bibr" rid="bib7">Dimitrov et al., 2008</xref>; <xref ref-type="bibr" rid="bib34">Nizak et al., 2003a</xref>; <xref ref-type="bibr" rid="bib50">Tanaka et al., 2007</xref>). We hypothesized that the NaLi-H1 synthetic library had enough diversity and functionality to enable the identification of selective conformational binders. A subtractive panning was performed to select conformation-specific antibodies directed against small GTPases from the RHO subfamily (<xref ref-type="bibr" rid="bib5">Chinestra et al., 2012</xref>). Small GTPases are molecular switch that cycle between an inactive and an active state when bound to GDP or GTP nucleotides, respectively. Mutant of small GTPases can be designed that adopt stably an active or inactive conformation. A constitutively active (CA) mutant RHOA L63 was expressed in HEK293 as a bait then freshly pulled down for panning to preserve its native conformation. To enrich in phage specific for GTP-bound RHOA, a depletion step was introduced from the second round of panning using GDP-bound RHO proteins. After four rounds of selection, clones were analyzed using phage ELISA against either wild type RHOA loaded with GTPγS (a non-hydrolysable analogue of GTP) or GDP-loaded RHOA. Forty clones presenting a differential ELISA signal in favor of the GTP loaded RHOA were sequenced. One antibody, represented by clone H12, represented more than 50% of the population. We analyzed H12 binding specificity by ELISA on several purified RHO proteins expressed as GST fusion in <italic>E.coli.</italic> H12 recognized the constitutively active mutant RHOA L63 (RHOA-CA) which is bound to GTP due to impaired hydrolysis activity. A similar signal was obtained with wild type RHOA loaded with the non-hydrolysable GTP analogue GTPγS. In contrast, no binding was observed to the dominant negative RHOA N19 mutant RHOA-DN nor to GDP-loaded wild type RHOA (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). The capacity of H12 to specifically immunoprecipitate GTP-loaded RHOA from mammalian cell extracts was then evaluated in comparison to the standard method to assay RHO activity (<xref ref-type="bibr" rid="bib42">Ren et al., 1999</xref>). This pull down method is based on the RHO binding domain of Rhotekin fused to GST (GST-RBD) which is known to bind to the active conformation of RHO GTPase. The hs2dAb H12 bearing a carboxy-terminal CBD (Chitin-Binding Domain) was expressed in <italic>E. coli</italic> and immobilized on chitin beads. These beads were then incubated with HeLa cell extracts pre-treated with either GTPγS or GDP to load small GTPases with the respective nucleotide. The H12 hs2dAb was found to be highly selective of RHO loaded with GTPγS as it was unable to precipitate RHO from GDP loaded extract (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). A similarly strong conformation-specificity was found when using H12 for immunofluorescence staining (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). HeLa cells expressing the GFP-RHOA constitutively active mutant carrying the mutation Q63L (GFP-RHOA CA) or the dominant negative mutated T19N (GFP-RHOA DN), were fixed and stained with H12 hs2dAb. Expression of the dominant negative mutant GFP-RHOA DN, did not lead to an increased signal over the background of un-transfected cells. In contrast, a staining with H12 was correlated with the level of GFP-RHOA CA mutant expression. Note that the signal does not fully overlap GFP fluorescence and appeared stronger at the cell border and in large zone where cell shape is strongly retracted by large bundled actin stress fibers induced by a sustained activation of the RHOA/ROCK pathway (<xref ref-type="bibr" rid="bib28">Mayer et al., 1999</xref>). This CA mutant, like active mutant of many small GTPases related to RAS still need to be activated by guanine nucleotide exchange factors to be loaded with GTP and display the active conformation. Thus, we believe that the H12 staining revealed the active form of this mutant in cells (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). All together, these results demonstrated that the H12 hs2dAb is selective for RHO GTPases in their active conformation, highlighting the performance and diversity of the NaLi-H1 library.<fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.16228.012</object-id><label>Figure 3.</label><caption><title>Subtractive selection led to conformational or cell type specific hs2dAbs.</title><p>(<bold>A</bold>–<bold>C</bold>) H12 is a conformational hs2dAb binding only to the GTP bound, activated state, of the RHOA GTPase: (<bold>A</bold>) ELISA using the H12 or anti-GST antibodies to reveal recombinant GST-RHOA wild type proteins loaded with either 100 µM GTP gamma S (Black) or 1 mM GDP (White), or constitutively active mutant proteins GST-RHOA Q63L (Grey). Means ± SEM. (<bold>B</bold>) A CBD tagged H12 pull down from HeLa cell extract loaded with100 µM GTP gamma S (GTP) or with 1 mM GDP as inputs. Western blot reveals RHOA at a similar level in 5% of both input but only on the GTP loaded extract in the CBD-H12 pull down. D5 anti tubulin was used as a negative control and the standard GST-RBD (RHO binding domain of Rhotekin) as a positive control of active RHO pull down. (<bold>C</bold>) Immunofluorescence on HeLa cells overexpressing GFP-RHOA CA (constitutively active) mutant or GFP-RHOA DN dominant negative mutant. H12 staining detected using a myc tag antibody revealed only cells overexpressing the constitutively active mutant with a pattern stronger at the cell periphery were RHOA activation is high. (<bold>D</bold>) Tumor cell surface subtractive selection scheme. (<bold>E</bold>) ELISA of hs2dAb F7 anti-HER2 on HER2 fused with a rabbit Fc versus binding on rabbit Fc at equimolar concentration. (<bold>F</bold>) hs2dAb F7 anti-HER2 decorated the SKBR3 membrane in immunofluorescence. SKBR3 cells were fixed with 3% paraformaldehyde and stained with F7 revealed by an anti-HisTag (Sigma) and an anti-MouseCy3 secondary antibody (Jackson). (<bold>G</bold>) FACS analysis of F7 anti-HER2 on SKBR3 HER2 positive cells versus MCF10A HER2 negative cells. (Scale bar = 10 µm).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16228.012">http://dx.doi.org/10.7554/eLife.16228.012</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-16228-fig3-v2"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.16228.013</object-id><label>Figure 3—figure supplement 1.</label><caption><title>non cropped western blot corresponding to <xref ref-type="fig" rid="fig3">Figure 3B</xref> detection RHOA.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16228.013">http://dx.doi.org/10.7554/eLife.16228.013</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-16228-fig3-figsupp1-v2"/></fig></fig-group></p></sec><sec id="s2-5"><title>Direct selection against cell surface antigens</title><p>The use of antibodies to target cells involved in pathologies like cancers or viral infection is one of the most promising therapeutic approach. Antibodies also represent a unique tool to identify novel targets at the cell surface. Using synthetic libraries like the NaLi-H1 library to carry out direct selection against the cell surface of tumor cells would strongly accelerate the identification of specific antigens while allowing extended control over the conditions of selection. A subtractive selection scheme was set up to identify antibodies selectively detecting the surface of breast tumor cells: phages displaying hs2dAbs were first depleted against a reference cell line before being selected against the target one (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). As a target cell line, we used the SKBR3 line, which is known to overexpress the HER2 cell surface protein, while the MCF7 cell line, negative for HER2, was used to pre-adsorb the library. After the third round of bio-panning, 88 clones were analyzed by FACS and 58 were found to be positive when tested on SKBR3 cells and negative on MCF7 cells. Sequencing the 58 positive clones revealed that 15 independent binders had been selected. Although the subtractive selection was not performed on identical cell lines expressing or not HER2, we observed strikingly that 12 clones out of 15 recognized HER2 exoplasmic domain by ELISA using HER2-Fc as a target antigen (<xref ref-type="fig" rid="fig3">Figure 3E</xref>), suggesting that it behaves as a dominant differential epitope. As shown in <xref ref-type="fig" rid="fig4">Figure 4</xref>, these antibodies efficiently detected HER2 at the cell surface by immunofluorescence (<xref ref-type="fig" rid="fig3">Figure 3F</xref>) or by FACS (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). These experiments demonstrated that the NaLi-H1 library will represent a unique tool to discover, in a rapid and cost effective manner, specific antibodies detecting antigens present at the surface of pathological cells. These antibodies may then be used to identify the corresponding target.<fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.16228.014</object-id><label>Figure 4.</label><caption><title>Fluorescent intrabodies tracking endogenous proteins.</title><p>Intracellular expression of hs2dAb. (<bold>A</bold>) (top panel) HeLa cells were co-transfected with GFP-Rab6 and a hs2dAb-mCherry anti-EGFP plasmids. The hs2dAb mCherry anti-EGFP colocalized perfectly with the Rab6 Golgi staining. (bottom panel) HeLa cells were co-transfected with Myr-palm-mCherry and a VHH-EGFP anti-mCherry plasmids. The VHH-EGFP anti-mCherry interacted with its target in vivo and colocalized perfectly with the mCherry staining at the plasma membrane. (<bold>B</bold>) SKBR3 cells were transfected with an anti-p53 hs2dAb-mCherry alone (top panel), or together with full length p53-EGFP which concentrated the hs2dAb into the nucleus (bottom panel). (<bold>C</bold>) GFP, used as a control (top panel) or a GFP-tagged anti-HP1 hs2dAb (bottom panel) were transiently expressed in HeLa cells (green). In contrast to the GFP control, the GFP-tagged anti-HP1 strongly accumulated in the nucleus where it labeled nuclear condensations. (Scale bar = 10 µm)</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16228.014">http://dx.doi.org/10.7554/eLife.16228.014</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-16228-fig4-v2"/></fig></p></sec><sec id="s2-6"><title>hs2dAbs as intracellular antibodies</title><p>Various antibody fragments have long been proposed to represent powerful tools when expressed in cells as intrabodies. Although several studies indeed report efficient use of intrabodies (reviewed in [<xref ref-type="bibr" rid="bib20">Kaiser et al., 2014</xref>; <xref ref-type="bibr" rid="bib25">Lobato and Rabbitts, 2003</xref>; <xref ref-type="bibr" rid="bib48">Stocks, 2005</xref>]), this is limited to antibody scaffolds that resist to the reducing environment of the cytosol. We evaluated the use of the hs2dAb scaffold to develop intrabodies. Randomly chosen hs2dAbs were fused to a fluorescent protein and observed in living cells. In comparison to our previous experience with scFv or nanobody libraries in which a majority of tested antibodies showed aggregation when expressed in the cytosol as an EGFP-fusion, most of the hs2dAbs tested here gave a monodispersed fluorescence, and very few were showing aggregates. Monodispersed fluorescence of the EGFP has been proposed to be a convenient indicator of stability and potential use as intrabody (<xref ref-type="bibr" rid="bib13">Guglielmi et al., 2011</xref>). Several hs2dAb directed against actin, tubulin, EGFP or p53 were tested for their ability to trace intracellular antigens in living cells. None of the anti-tubulin or anti-actin antibodies tested were found localized on microtubule or microfilament, respectively, in living cells. We reasoned that this poor efficiency may be linked to the antigen denaturating conditions used during the selection of antibodies directed against actin. The existence of a large pool of unpolymerized actin and tubulin may also prevent efficient recruitment on the polymers. In contrast, several anti-GFP and anti-mCherry hs2dAbs were found to efficiently label their targets, like for example GFP-Rab6 or Myr-Palm-mCherry fusion proteins, in living cells (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Similarly, the anti-p53 hs2dAb fused to mCherry were clearly accumulated in the nucleus of SKBR3 cells where endogenous p53 is also localized. This signal was enhanced in cells overexpressing p53-EGFP (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). This further confirmed the binding specificity of the hs2dAb anti-p53 while expressed in the reducing cytosol. Effective intrabodies were also obtained against HP1. <xref ref-type="fig" rid="fig4">Figure 4C</xref> (lower panel) shows that anti-HP1 expressed as an EGFP tagged protein in HeLa cells localized in the nucleus where it labels condensed structures similar to HP1 usual staining. In contrast, a diffuse cytoplasmic and nuclear staining was obtained using non relevant hs2dAbs fused to EGFP (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, upper panel).</p><p>These results indicate that functional intrabodies can be obtained at high frequency using the NaLi-H1 library. Intrabodies can be used, upon fusion with a fluorescent protein, to track the dynamics of their target in living cells (see for example <xref ref-type="bibr" rid="bib34">Nizak et al., 2003a</xref>). Such an application is illustrated in the <xref ref-type="other" rid="media1">Video 1</xref> where an hs2dAb directed against mCherry is used to track mCherry-fused Rab6 in living cells. Intrabodies may allow not only to track the dynamics of their cellular target, but also to perturb, or block, their activity. Our results indeed indicate that the H12 antibody was able to perturb endogenous RHO activity when expressed in the cytosol. We could not directly image enrichment of the H12 antibodies in cellular sub-domains in living cells but we observed that H12 may behave as an efficient intrabody carrying out co-immunoprecipitation experiments. H12 carrying a carboxy-terminal myc tag was expressed in HeLa cells together with either the CBD-fused RHOA DN or with the CBD-RHOA CA mutants. H12 was pulled-down by RHOA CA but not by inactive RHOA DN (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). H12 thus worked as an intrabody and kept its conformation sensitivity in the cytosol. Because RHO GTPases are involved in signaling pathways that promotes the actin cytoskeleton polymerization, we looked at functional effects induced by H12 overexpression. In contrast to un-transfected cells or cells transfected with various non-relevant EGFP fused hs2dAb (<xref ref-type="fig" rid="fig5">Figure 5A</xref>, upper panel), we observed that cells expressing H12-EGFP were totally devoid of actin stress fibers (<xref ref-type="fig" rid="fig5">Figure 5A</xref>, lower panel). This alteration in actin filament organization was associated with marked changed in cell shape characteristic of loss of intracellular mechanical forces and tension. As RHOA plays a major role in activating myosin II and actin cytoskeleton reorganization, our results suggested that H12 efficiently perturbed RHO-dependent signaling, mimicking the phenotype induced by the C3 exoenzyme RHO inhibitor (<xref ref-type="bibr" rid="bib43">Ridley and Hall, 1992</xref>).<media content-type="glencoe play-in-place height-250 width-310" id="media1" mime-subtype="mp4" mimetype="video" xlink:href="elife-16228-media1.mp4"><object-id pub-id-type="doi">10.7554/eLife.16228.015</object-id><label>Video 1.</label><caption><title>mcherry-Rab6 was transiently expressed in HeLa cells together with an anti-mCherry hs2dAb fused to GFP. 24 hr after transfection, cells were imaged using a spinning disk confocal microscope.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16228.015">http://dx.doi.org/10.7554/eLife.16228.015</ext-link></p></caption></media><fig-group><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.16228.016</object-id><label>Figure 5.</label><caption><title>Targeting cellular proteins using inhibitory antibodies or by functionalizing antibodies to induce protein knockdown.</title><p>(<bold>A</bold>) HeLa cells expressing transiently a EGFP-tagged non relevant hs2dAB (top panel) or EGFP-H12 anti RHO-GTP (bottom panel) were fixed 20 hr post transfection and stained using DAPI and Alexa 594 phalloidin to detect actin stress fibers. The H12 hs2dAb induced actin stress fibers disappearance and major cell shape change (see cells outlined with a dotted line) (<bold>B</bold>) Protein knockdown of H2B-EGFP mediated by functionalized inhibitory antibodies. HeLa S3 cell stably expressing histone H2B-EGFP were transfected with vectors expressing antibodies fused to an F-box (F-Ib) to induce degradation of the targeted cellular antigen. The F-GFP4 VHH (DegradFP) was used as a positive control (top panel) and a non-relevant hs2dAb as a negative control (bottom panel). F-Ib were expressed using a bi-cistronic vector driving the co-expression of mitochondrial targeted mCherry. Protein interference is analyzed in cells displaying mCherry positive mitochondria (mitoCherry channel). Efficient protein knockdown is obtained using the R3TF3 anti-EGFP intrabody. Note that not all nanobodies can be used as F-Ib because R3TG4 does not induce protein degradation. (Scale bars = 20 µm) (<bold>C</bold>) Fluorescence decay measurement of the protein interference assay was quantified by flow cytometry (10000 cells analyzed, from 3 independent replicates). GFP fluorescence intensity was quantified in the transfected and the untransfected subpopulations for each F-Ib. The ratio of each median of fluorescence (transfected versus untransfected population) was calculated as a percentage of GFP fluorescence intensity for one F-Ib. A strong decrease in fluorescence corresponding to protein knockdown was observed with F-GFP4 VHH and F-R3TF3 hs2dAb intrabodies while the non-relevant negative control and R3TG4 did not induce a decrease of fluorescence. (<bold>D</bold>) Cells were analyzed as in C but the cells were incubated in 1 µM MG132 or DMSO for 44 hr after transfection by the different F-Ib and fluorescence intensity was normalized using the non-relevant control. Protein knockdown was inhibited by MG132.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16228.016">http://dx.doi.org/10.7554/eLife.16228.016</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-16228-fig5-v2"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.16228.017</object-id><label>Figure 5—figure supplement 1.</label><caption><title>Conformational selectivity of the H12 intrabody towards RHOA.GTP.</title><p>HeLa cells were co-transfected for 24 hr with the anti RHO hs2dAb H12 fused to carboxy-terminal myc tag (H12-myc) or a non relevant control (NR-myc) that was a negative clone in a panning against FITC together with chitin binding domain (CBD) fusion of either the dominant negative mutant RHOA-N19 (DN) or the constitutively active mutant RHOA-L63 locked in the GTP bound state (CA). Chitin beads pull down of CBD-RHOA-DN or CBD-RHOA-CA revealed the selective co-precipitation of H12-myc together with the RHO active mutant. The total level of CBD-RHOA or hs2dAb-myc proteins was revealed by loading 5% of the respective input. CBD-RHOA proteins were detected with anti CBD tag and the hs2dAb antibodies with an anti-myc tag antibody.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16228.017">http://dx.doi.org/10.7554/eLife.16228.017</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-16228-fig5-figsupp1-v2"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.16228.018</object-id><label>Figure 5—figure supplement 2.</label><caption><title>Protein knockdown set up using F-Ib degradation with anti-GFP intrabodies.</title><p>(<bold>A</bold>) Model for F-Ib degradation by fusing Fbox domain to the VHH GFP4 inducing GFP target protein ubiquitiation followed by proteasome-dependent degradation of the target protein. (<bold>B</bold>) Schematic illustration of the bicistronic vectors: an Fbox or NoFbox domain, respectively, is fused to the N terminal part of hs2dAb and a transfection marker MTS-mCherry, labeling mitochondria in red, is co-expressed using an Internal Ribosome Entry Site (IRES). (<bold>C</bold>) Fluorescence visualization HeLa S3 cells stably expressing H2B-GFP and transfected with NoF-VHH GFP4 or F-VHH GFP4. Degradation by the degradFP was observed in cells expressing F-VHH GFP4. Scale bar = 10 µm (<bold>D</bold>) Western blot quantification of protein knockdown mediated by F-GFP4. (<bold>E</bold>) Quantification of GFP fluorescence by flow cytometry in MTS Cherry positive cells.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16228.018">http://dx.doi.org/10.7554/eLife.16228.018</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-16228-fig5-figsupp2-v2"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.16228.019</object-id><label>Figure 5—figure supplement 3.</label><caption><title>non cropped western blot corresponding to <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref> detection of RHOA, Myc tagged hs2dAb intrabodies, and GAPDH which is not in the main figure.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16228.019">http://dx.doi.org/10.7554/eLife.16228.019</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-16228-fig5-figsupp3-v2"/></fig><fig id="fig5s4" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.16228.020</object-id><label>Figure 5—figure supplement 4.</label><caption><title>non cropped western blot corresponding to <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref> detection of tubulin, GFP and myc tag.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16228.020">http://dx.doi.org/10.7554/eLife.16228.020</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-16228-fig5-figsupp4-v2"/></fig></fig-group></p><p>Identification of blocking antibodies is a challenging task and not all functional intrabodies are inhibitory. However, it is possible to functionalize non-blocking intrabodies to inhibit their target function. One approach relies on the ubiquitinylation and degradation of the recognized target as described by <xref ref-type="bibr" rid="bib4">Caussinus et al. (2011)</xref>. This approach is based on the fusion of intrabodies to an F-box domain which allows interaction with Skip1, a member of the SCF complex, an E3 ubiquitin ligase of the complex E1/E2/E3 ubiquitinylation machinery, that targets proteins to proteasome-dependent cellular degradation (<xref ref-type="bibr" rid="bib4">Caussinus et al., 2011</xref>) (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). This approach was efficiently developed to target several EGFP fusion proteins in <italic>Drosophila</italic> using a single anti EGFP intrabody, named GFP4, which is a robust and high affinity EGFP llama intrabody originally isolated from an immune library (<xref ref-type="bibr" rid="bib44">Rothbauer et al., 2006</xref>). To get insight into the relative functionality of hs2dAb for such a protein interference approach, several of the anti EGFP hs2dAb selected from the NaLi-H1 library were fused at their amino terminus to the Fbox domain and their efficacy was compared to the efficacy of the Fbox-GFP4 nanobody. To detect cells expressing Fbox-intrabody fusion proteins (F-Ib), we constructed a bicistronic vector driving the co-expression of F-Ib together with a mitochondria-targeted mCherry (Mito-mCherry) (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). We expressed the F-Ib antibodies in a HeLa clone stably expressing EGFP fused to histone H2B (<xref ref-type="bibr" rid="bib47">Silljé et al., 2006</xref>) and looked for EGFP-H2B depletion. As expected, F-GFP4, also known as degradFP, induced a strong reduction of H2B-EGFP expression as analyzed by western blot (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). Accordingly, a strong reduction in nuclear fluorescence intensity was observed in cells expressing F-GFP4 (see mito-mCherry positive cells, <xref ref-type="fig" rid="fig5">Figure 5B</xref>; <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). No effect was observed when expressing either GFP4 alone or a GFP4 fused to a truncated, nonfunctional, Fbox domain (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). When anti-EGFP clones selected from the NaLi-H1 library were tested, we observed that some of the hs2dAb that were found to active as fluorescent intrabodies failed to degrade H2B-EGFP when expressed as F-Ib. This highlights the fact that not all intrabodies can efficiently be functionalized with the F-box and that in vivo binding to a target is not the only parameter to consider. However, several hs2dAb anti-EGFP induced a complete disappearance of nuclear H2B-EGFP signal when expressed as F-Ib (F-R3TF3, <xref ref-type="fig" rid="fig5">Figure 5B</xref>) while no reduction was observed when using an anti-EGFP that cannot be used as an intrabody (F-R3TG4, <xref ref-type="fig" rid="fig5">Figure 5B</xref>). FACS analysis showed a decreased of fluorescence intensity by as much as 70% (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). As expected, this effect was reversed in the presence of a proteasome inhibitor (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Altogether, these experiments show that the hs2dAb scaffold enables the frequent selection of antibodies that can be expressed in the mammalian cell cytoplasm to be used as functional fluorescent or inhibitory intrabodies.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Here, we report the construction of the first large fully synthetic single domain antibody library based on a humanized scaffold derived from llama VHH. A set of robust nanobody scaffolds was first identified using a positive expression screening in <italic>E. coli</italic> cytosol. One very robust scaffold (sdAb<sup>D10</sup>) was identified and was used as a base. After introduction of several modifications that aimed at humanizing its primary sequence, we designed the hs2dAb scaffold which is as stable as sdAb<sup>D10</sup> while being closer to human VH3. Our data indicate that the hs2dAb displays partial resistance and/or refolding after treatment for 10 min at 90°C. Using CDR grafting experiments we confirmed the efficacy and the stability of the synthetic scaffold to display CDR regions. Based on our prior experience on phage display libraries, immune or naïve llama VHH libraries (<xref ref-type="bibr" rid="bib31">Monegal et al., 2012</xref>; <xref ref-type="bibr" rid="bib37">Olichon and Surrey, 2007</xref>) or from scFv libraries (<xref ref-type="bibr" rid="bib7">Dimitrov et al., 2008</xref>; <xref ref-type="bibr" rid="bib10">Goffinet et al., 2008</xref>; <xref ref-type="bibr" rid="bib34">Nizak et al., 2003a</xref>) we then rationally designed CDR diversity with fixed CDR1 and CDR2 size and four CDR3 sizes (9, 12, 15 or and 18 amino acids). The power of modern gene synthesis approach permits to reach very high genetic diversity while controlling codon bias and cloning features. Fully random codon combination using NNN or NNK trinucleotide cannot prevent stop codon, undesired cysteine or hydrophobic residues to be incorporated, and it does not lead to the controlled probability of amino acid occurrence at a given position. Therefore a more rational design was implemented with defined set of codons for each CDR amino acid position so that it does not mimic natural diversity, in contrast to recently developed Fab synthetic libraries (<xref ref-type="bibr" rid="bib41">Prassler et al., 2011</xref>; <xref ref-type="bibr" rid="bib57">Zhai et al., 2011</xref>), but is rather optimized for intrinsic hydrophilicity or solubility. After a large-scale cloning of synthetic fragments, 3 billion independent clones were transformed in the bacteria. Library quality was confirmed by Sanger and next generation sequencing.</p><p>The library was validated by screening against various targets and in each case specific and highly functional antibodies were obtained (<xref ref-type="table" rid="tbl1">Table 1</xref>). Various selection schemes yielded a large diversity of high affinity and high selectivity binders. Selections were carried out using purified antigen coated on polystyrene, on magnetic beads or directly on the cell surface. In many cases, two rounds of selection were sufficient to obtain selective binders. We usually analyzed only 80 randomly picked clones because the diversity of specific binders was systemically high. Only a few selections led to antibodies usable in western blotting (anti-actin, ant-tubulin) probably because most screenings were done using natively folded targets. Accordingly, selected hs2dAb performed very well in other conventional immunoassays like ELISA, FACS, immunoprecipitation or immunofluorescence. Affinity measurements done by surface plasmon resonance revealed KD values in the order of 10 nanomolar and up to 50 picomolar. Such high affinities are rather good and usually rarely observed for monovalent binders obtained without in vivo immunization or in vitro affinity maturation steps (<xref ref-type="fig" rid="fig6">Figure 6</xref>; <xref ref-type="table" rid="tbl2">Table 2</xref>).<table-wrap id="tbl1" position="float"><object-id pub-id-type="doi">10.7554/eLife.16228.021</object-id><label>Table 1.</label><caption><p>Summary of screenings showing the number of unique clones giving positive signal. (ND means non determined)</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16228.021">http://dx.doi.org/10.7554/eLife.16228.021</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom"/><th align="center" colspan="3" valign="bottom"><p>Positive clones</p></th><th valign="bottom"/></tr><tr><th valign="bottom">Antigen</th><th valign="bottom">Phage ELISA</th><th valign="bottom">IF/FACS</th><th valign="bottom">Intrabody</th><th valign="bottom">Rounds of panning</th></tr></thead><tbody><tr><td><bold>GFP</bold></td><td>37</td><td>10/ND</td><td>4/10</td><td>2</td></tr><tr><td><bold>mCherry</bold></td><td>ND</td><td>6/ND</td><td>2/6</td><td>3</td></tr><tr><td><bold>Tubulin</bold></td><td>ND</td><td>3/ND</td><td>0/3</td><td>2</td></tr><tr><td><bold>Actin</bold></td><td>16</td><td>7/ND</td><td>1/7</td><td>3</td></tr><tr><td><bold>p53</bold></td><td>12</td><td>6/ND</td><td>2/6</td><td>2</td></tr><tr><td><bold>RHOA-GTP</bold></td><td>24</td><td>8/ND</td><td>3/8</td><td>4</td></tr><tr><td><bold>Her2</bold></td><td>6</td><td>5/10</td><td>ND</td><td>3</td></tr></tbody></table></table-wrap><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.16228.022</object-id><label>Figure 6.</label><caption><title>Affinity determination.</title><p>Single cycle kinetics analysis was simultaneously performed on immobilized His fusion VHH antibodies (250–300 RU), with five injections of analytes (EGFP, HER2, RHOAQ63L and mCherry) at 3.125 nM, 6.25 nM, 12.5 nM, 25 nM, and 50 nM. Analytes injections lasted for 120 s each and were separated by 10 s dissociation phases. At this time of buffer exchange, a slight refraction index discrepancy between the sample and the flow buffer can induce a drop in resonance unit. This common bulk effect, which is clearly visible on sensorgrams with a smaller scale range on the RU axis (ie: R3SE4, R2TB5), does not affect the measurement of off-rate constant. Off-rate constant was calculated from an extended dissociation period of 10 min following the last injection according to the single cycle kinetics method. Each sensorgram (expressed in RUs as a function of time in seconds) represents a differential response where the response on an empty reference channel (Fc1) was subtracted. The red curves correspond to the data and the black curves represent the fit done by the BIAevaluation software. Note that the fitted curve is almost identical to the data curve in some cases like for example the RHOA Q63L or the HER2 binding measurement.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16228.022">http://dx.doi.org/10.7554/eLife.16228.022</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-16228-fig6-v2"/></fig><table-wrap id="tbl2" position="float"><object-id pub-id-type="doi">10.7554/eLife.16228.023</object-id><label>Table 2.</label><caption><p>Binding affinities of 9 selected hs2dAb fused to a 6HIS tag measured by surface plasmon resonance single cycle kinetics method. Dissociation equilibrium constant KD corresponds to the ratio between off-rate and on-rate kinetic constant K<sub>off/</sub>K<sub>on</sub>. Non relevant hs2dAb were used as negative controls and gave no detectable binding signal. A positive control endowed with subnanomolar affinity, the GFP binder VHH-GFP4, was analyzed in parallel to the GFP hs2dAbs. A KD of 1.55<sup>–10</sup> M was measured for VHH-GFP4 which is similar to published values. The binding properties of the conformational H12 hs2dAb to the GTP loaded RHOA subfamily were measured using the L63 or L61 constitutively active mutants of RHO, RHOB, RHOC, RAC1 and CDC42 related small GTPases, as well as the negative mutant T19N of RHOA. ('no' means no detectable binding). </p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16228.023">http://dx.doi.org/10.7554/eLife.16228.023</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom">hs2dAb-6xHis</th><th valign="bottom">Antigen</th><th valign="bottom"><bold><italic>k</italic><sub>on</sub> (M<sup>−1</sup> s<sup>−1</sup>)</bold></th><th valign="bottom"><bold><italic>k</italic><sub>off</sub> (s<sup>−1</sup>)</bold></th><th valign="bottom"><bold>KD(M)</bold></th></tr></thead><tbody><tr><td valign="bottom">R2TB5 anti-GFP</td><td valign="bottom">GFP</td><td valign="bottom">1.24 10<sup>+6</sup></td><td valign="bottom">3.05 10<sup>−4</sup></td><td valign="bottom"><bold>2.45 10<sup>−10</sup></bold></td></tr><tr><td valign="bottom">R3SD1 anti-GFP</td><td valign="bottom">GFP</td><td valign="bottom">7.07 10<sup>+5</sup></td><td valign="bottom">6.68 10<sup>−4</sup></td><td valign="bottom"><bold>9.44 10<sup>−10</sup></bold></td></tr><tr><td valign="bottom">R3SE4 anti-GFP</td><td valign="bottom">GFP</td><td valign="bottom">1.45 10<sup>+5</sup></td><td valign="bottom">5.83 10<sup>−4</sup></td><td valign="bottom"><bold>4.01 10<sup>−9</sup></bold></td></tr><tr><td valign="bottom">Llama VHH GFP4</td><td valign="bottom">GFP</td><td valign="bottom">2.99 10<sup>+5</sup></td><td valign="bottom">4.65 10<sup>−5</sup></td><td valign="bottom"><bold>1.55 10<sup>−10</sup></bold></td></tr><tr><td valign="bottom">D4 anti-Her2</td><td valign="bottom">Her2</td><td valign="bottom">1.79 10<sup>+5</sup></td><td valign="bottom">1.63 10<sup>−4</sup></td><td valign="bottom"><bold>9.11 10<sup>−10</sup></bold></td></tr><tr><td valign="bottom">A10 anti-Her2</td><td valign="bottom">Her2</td><td valign="bottom">1.66 10<sup>+4</sup></td><td valign="bottom">4.88 10<sup>−5</sup></td><td valign="bottom"><bold>2.94 10<sup>−9</sup></bold></td></tr><tr><td valign="bottom">B9 anti-Cherry</td><td valign="bottom">mCherry</td><td valign="bottom">6.14 10<sup>+4</sup></td><td valign="bottom">1.68 10<sup>−4</sup></td><td valign="bottom"><bold>2.74 10<sup>−9</sup></bold></td></tr><tr><td valign="bottom">E4 anti-Cherry</td><td valign="bottom">mCherry</td><td valign="bottom">6.57 10<sup>+4</sup></td><td valign="bottom">2.03 10<sup>−4</sup></td><td valign="bottom"><bold>3.10 10<sup>−9</sup></bold></td></tr><tr><td valign="bottom">B3 anti-Cherry</td><td valign="bottom">mCherry</td><td valign="bottom">6.19 10<sup>+4</sup></td><td valign="bottom">2.71 10<sup>−4</sup></td><td valign="bottom"><bold>4.38 10<sup>−9</sup></bold></td></tr><tr><td valign="bottom">H12 anti-RHO.GTP</td><td valign="bottom">RHOA Q63L</td><td valign="bottom">4.81 10<sup>+5</sup></td><td valign="bottom">1.28<sup>−4</sup></td><td valign="bottom"><bold>2.65 10<sup>−10</sup></bold></td></tr><tr><td valign="bottom">H12 anti-RHO.GTP</td><td valign="bottom">RHOB Q63L</td><td valign="bottom">2.24 10<sup>+5</sup></td><td valign="bottom">3.59<sup>−4</sup></td><td valign="bottom"><bold>1.57 10<sup>−9</sup></bold></td></tr><tr><td valign="bottom">H12 anti-RHO.GTP</td><td valign="bottom">RHOC Q63L</td><td valign="bottom">1.12 10<sup>+6</sup></td><td valign="bottom">5.41<sup>−5</sup></td><td valign="bottom"><bold>4.79 10<sup>−11</sup></bold></td></tr><tr><td valign="bottom">H12 anti-RHO.GTP</td><td valign="bottom">RHOA T19N</td><td valign="bottom">no</td><td valign="bottom">no</td><td valign="bottom">no</td></tr><tr><td valign="bottom">H12 anti-RHO.GTP</td><td valign="bottom">RAC1 Q61L</td><td valign="bottom">7.53 10<sup>+5</sup></td><td valign="bottom">2.55<sup>−4</sup></td><td valign="bottom"><bold>3.3 10<sup>−10</sup></bold></td></tr><tr><td valign="bottom">H12 anti-RHO.GTP</td><td valign="bottom">CDC42 Q61L</td><td valign="bottom">no</td><td valign="bottom">no</td><td valign="bottom">no</td></tr></tbody></table></table-wrap></p><p>The NaLi-H1 library thus enables the rapid selection of diverse and highly functional binders. Because it is a fully synthetic, non immune, library, it does not depend on animal experimentation, it is not limited by natural immunogenicity or toxicity of antigens and allows to develop and adjust the selection without ethic consideration. In addition, because all steps are carried out in vitro, conditions can be tightly controlled. This allowed to develop powerful differential selection and to identify conformation-specific antibodies. This also allowed to directly screen for antibodies directed against antigens specifically present at the surface of a particular cell type. Such a differential selection will be a powerful approach to identify novel antigen at the surface of tumor or infected cells. Such antibodies may also represent powerful tools for diagnostic and therapeutic applications to target cells in human pathologies. For example, after dimerization using Fc domains, hs2dAb antibodies may be used to target tumor cells and benefit from antibody-dependent cell-mediated cytotoxicity (ADCC) for example. They may also be used directly as the smallest antibody-derived domain naked as an agonist or antagonist or armed for enhanced toxicity. Similarly, it may be labeled using radioactive compounds (e.g. <sup>99</sup>mTc, <sup>111</sup>In, <sup>64</sup>Cu) and used to image tumors in patient using positron emission tomography. Altogether, he NaLi-H1 library may accelerate the identification of novel potent tools to be used in human clinical applications.</p><p>The synthetic scaffold we defined was based on the selection of a set of VHH able to fold properly in the bacteria cytosol. The goal was not only to define a robust scaffold that would be efficiently produced without aggregation but also to allow frequent selection of functional intrabodies. Intrabodies have been isolated from various antibody libraries (<xref ref-type="bibr" rid="bib34">Nizak et al., 2003a</xref>; <xref ref-type="bibr" rid="bib44">Rothbauer et al., 2006</xref>; <xref ref-type="bibr" rid="bib51">Tanaka and Rabbitts, 2010</xref>; <xref ref-type="bibr" rid="bib53">Vercruysse et al., 2010</xref>) as well as other protein scaffold like Darpin (<xref ref-type="bibr" rid="bib49">Tamaskovic et al., 2012</xref>) or FN3 (<xref ref-type="bibr" rid="bib23">Koide et al., 2012</xref>) which are devoid of cysteine. A peculiar feature of the NaLi-H1 library is that it is based on a humanized nanobody-like robust scaffold, stable in a reducing environment, while it still contains the two canonical cysteine residues. Stabilized nanobodies, human single domain scaffolds (<xref ref-type="bibr" rid="bib6">Christ et al., 2007</xref>; <xref ref-type="bibr" rid="bib45">Saerens et al., 2005</xref>) and libraries (<xref ref-type="bibr" rid="bib11">Goldman et al., 2006</xref>; <xref ref-type="bibr" rid="bib26">Mandrup et al., 2013</xref>) were reported before. However, to our knowledge, no synthetic library producing at high frequency functional intrabodies was developed before based on such stabilized scaffolds. Almost every hs2dAb antibodies we expressed in mammalian cytosol showed no sign of aggregation, which further supported the idea that the synthetic scaffold we designed is robust and highly resistant to reduction. Previous studies showed that functional intrabody identification often relied on additional steps of selection in a protein–protein interaction reporter system such as PCA (<xref ref-type="bibr" rid="bib22">Koch et al., 2006</xref>) or bacterial 2 hybrid (<xref ref-type="bibr" rid="bib40">Pellis et al., 2012</xref>), yeast IACT (<xref ref-type="bibr" rid="bib51">Tanaka and Rabbitts, 2010</xref>) or F2H assays (<xref ref-type="bibr" rid="bib58">Zolghadr et al., 2008</xref>). Using the NaLi-H1 library, we observed that without using particular selection schemes, functional intrabodies were frequently obtained. Although we did not formally compare the NaLi-H1 library to previous llama naïve or semi synthetic libraries, the functionality of selected hs2dAb was compared to a sub-nanomolar affinity intrabody, the GFP4 nanobody, which has been extensively used (<xref ref-type="bibr" rid="bib4">Caussinus et al., 2011</xref>; <xref ref-type="bibr" rid="bib21">Kirchhofer et al., 2010</xref>). We observed by monitoring its signal-to-noise ratio and by using it in a protein knockdown assay that NaLi-H1 can provide highly functional hs2dAb which appeared as good as intrabodies from immune libraries.</p><p>Intrabodies can be used in several applications like tracking of intracellular dynamics of endogenous proteins (<xref ref-type="bibr" rid="bib34">Nizak et al., 2003a</xref>, <xref ref-type="bibr" rid="bib35">2003b</xref>; <xref ref-type="bibr" rid="bib44">Rothbauer et al., 2006</xref>) but the most appealing application is to use them for rapid protein inactivation in living cells. Intrabodies may be used to directly block their target proteins in cells. One of the conformation-sensitive antibody that was selected can be used to inhibit active RHO GTPase signaling in living cells and is as potent as the C3 exoenzyme toxin. Only few intrabodies have been described to be intrinsically inhibitors of protein activity (<xref ref-type="bibr" rid="bib15">Haque et al., 2011</xref>; <xref ref-type="bibr" rid="bib53">Vercruysse et al., 2010</xref>), and our results suggest that the NaLi-H1 library may enable rapid selection of inhibitory antibodies. The next challenge will be to select conformational sensors specifically directed against a particular member of closely related RHO subtypes (RHOA/B/C) which share more than 90% similarity in primary sequence. But in any case, our results show that the NaLi-H1 library allows the selection of efficient, conformation-specific, inhibitory intrabodies.</p><p>Another way intrabodies may be used to inactivate their targets in living cells is to fuse the intrabody to a dominant inhibitory domain. Following an idea pioneered by Affolter and colleagues (<xref ref-type="bibr" rid="bib4">Caussinus et al., 2011</xref>), we showed here that intrabodies selected from the NaLi-H1 library can be fused to a proteasome-targeting domain to impose the specific degradation of their respective targets. This protein interference approach was validated using anti-EGFP hs2dAb and we believe that this approach will bring disruptive tools to generate rapid protein knockdown both in cell culture and in the animal.</p><p>In summary, we have designed a novel nanobody scaffold endowed with improved stability and created a highly diverse library, the NaLi-H1 library, that was successfully screened to identify highly functional binders directed against very diverse targets. We believe that this library will allow the fast, and fully in vitro, identification of immunological tools usable both for fundamental and medical applications.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Plasmids and cloning</title><p>Artificial gene synthesis (Mr Gene, GmbH, Germany) composed of a 6His-Tag and a triple c-myc Tag was inserted into the pHEN2 phagemid vector (Griffin 1. library) between NotI and BamHI sites. CcdB gene from pENTR4 vector (Invitrogen - ThermoFisher Scientific, France) was inserted into the pHEN2 vector between NcoI and NotI sites. This vector allows to express antibody fragments in fusion, upstream, with the pelB leader to drive secretion in the periplasm and downstream with the PIII protein of M13 phages. An amber stop codon is present between the antibody and the pIII. This stop codon is partially suppressed in SupE <italic>E. coli</italic>. For expression and purification of dimeric antibodies, hs2dAb were inserted in vectors derived from pFuse (Invivogen, France) as described in <xref ref-type="bibr" rid="bib32">Moutel et al. (2009)</xref>. For intrabody expression in mammalian cells, hs2dAb were digested by NcoI and NotI and ligated into the pIb-mEGFP, pEGFP or the pmCherry vectors (Clontech - Takara, USA). (See the Appendix for more details).</p></sec><sec id="s4-2"><title>CAT filter assay</title><p>Previously selected VHHs from naïve or immune libraries were subcloned into pAOCAT (<xref ref-type="bibr" rid="bib31">Monegal et al., 2012</xref>) using the NcoI and NotI restriction sites. Chloramphenicol resistance assay was performed using BL21 (DE3) cells transformed with the pAOCAT-VHH fusion constructs. (See the Appendix for more details).</p></sec><sec id="s4-3"><title>Library construction</title><p>Details about the construction of the library can be found in the Appendix. In short, a synthetic design was ordered based on a statistic analysis of the diversity found in natural VHH and aiming at reducing hydrophobicity at some position. The size of the CDR1 and CR2 was fixed at 7 amino acids while 4 sizes of CDR3 were chosen (9, 12, 15 and 18 amino acids). Large -scale PCR was then carried out ensuring that at least 10<sup>10</sup> DNA molecules were used as a matrix. Fragments were then cut and inserted into the pHEN2-3myc plasmid. The ligated DNA material was used to transform electrocompetent <italic>E. coli</italic> TG1 cells (Lucigen Corp., Middleton, United States). Serial dilution was used to count the total number of bacteria transformed. A potential diversity of 3 × 10<sup>9</sup> was calculated. Transformed bacteria plated on 430 2xYT-ampicillin agar dishes (140 mm), grown overnight at 37°C, scrapped and stored in 30% of glycerol at −80°C.</p></sec><sec id="s4-4"><title>Ion torrent sequencing</title><p>IonTorrent sequencing library was prepared with the Ion Plus Fragment Library kit for AB Library Builder System (Life Technologies - TermoFisher Scientific, France) following manufacturer's instructions and was controlled on the Agilent 2100 Bioanalyzer (Agilent Technologies, France) with the High Sensitivity DNA Kit (Agilent Technologies). The sequencing template was prepared by emulsion PCR with the Ion OneTouch 2 system and the Ion PGM Template OT2 400 Kit (Life Technologies). Sequencing was performed on a IonTorrent Personal Genome Machine using the Ion PGM Sequencing 400 Kit and a 314v2 Ion chip (Life Technologies).</p></sec><sec id="s4-5"><title>Antigens</title><p>Human βActin was purchased from Sigma-Aldrich (France). RHOA GTPase fused to either an amino terminal Chitin Binding Domain or a streptactin binding peptide were produced in HEK293 cells. EGFP (as mCherry) in fusion with a streptavidine binding peptide (SBP) were produced through in vitro translation system (Roche Life Science, France) and used directly for screening without the need for purification.</p><p>Biotinylated Tubulin was purchased from Cytoskeleton, Inc. (Denver, United States). For p53, the 83 first amino acids of the NP_000537.3 isoform were produced in bacteria with a SNAP and His Tag, purified using Talon resin (Takara - Clontech) and biotinylated in vitro. HP1α was produced in bacteria with an avitag and a His Tag, and purified using Talon resin.</p><p>For HER2, the natural receptor was used as membrane protein target on SKBR3 cells.</p><p>For more details see the Appendix for more details.</p></sec><sec id="s4-6"><title>Phage display selections</title><p>Screening for ßactin was performed by panning in immunotubes as described (<xref ref-type="bibr" rid="bib27">Marks et al., 1991</xref>).Screening for EGFP, Tubulin and p53 were performed in native condition as described (<xref ref-type="bibr" rid="bib36">Nizak et al., 2005</xref>). Screening for HER2 was performed on surface cells as described (<xref ref-type="bibr" rid="bib8">Even-Desrumeaux and Chames, 2012</xref>). Screening on RHO was performed in native condition. (See the Appendix for more details).</p></sec><sec id="s4-7"><title>Enzyme-linked immunosorbent assay (ELISA)</title><p>Individual clones were screened by monoclonal phage ELISA as described. (See the Appendix for more details).</p></sec><sec id="s4-8"><title>Western-blot</title><p>After boiling in SDS-PAGE loading buffer, the samples were separated on a 12% SDS-PAGE and transferred to nitrocellulose membranes (Whatman GmbH, Germany). Membranes were blocked in 3% non-fat milk-PBS with 0.2% Tween 20 for 1 hr at room temperature or overnight at 4°C. unpurified hs2dAb were used at 1/100 from culture supernatant and added to the membranes with an anti-hisTag antibody at 1/3000 (Sigma-Aldrich) for 90 min. Blots were then washed and incubated 1 hr with secondary anti-Mouse HRP labeled antibodies (diluted at 1/10000 in PBS 0.1% Tween 20) (Jakson ImmunoResearch Laboratories). After 5 washes with PBS 0.1% Tween 20, secondary antibodies were then revealed using the SuperSignal chemoluminescent reagent (Pierce) and Hyperfilm ECL (GE HealthCare). For RHO-GTP pull down, the primary anti RHOA mAb was used (Cell Signaling Technology; 1/1000). For protein knockdown experiments, 500 000 of transfected cells (mCherry positive cells) were sorted with a MoFlo Astrios flow cytometer (Beckman Coulter). Cells were lysed with SDS-Tris lysis buffer (Tris pH7.4 10 mM, SDS 1% supplemented with phosphatase and protease inhibitors). 20 µg of cell extracts were separated on 12.5% SDS-PAGE and electro transferred onto PVDF membranes. Blots were probed with a rabbit polyclonal anti-EGFP full length (Santa Cruz, sc-8334, 1:500), a mouse monoclonal anti-α-tubulin (Sigma, T5168, 1:25000) and an anti-myc HRP antibody (Novus Biologicals, NB600-341, 1:40000). Detection was performed using peroxydase conjugated secondary antibodies and Pierce ECL Western Blotting Substrate (Thermo Scientific Pierce).</p></sec><sec id="s4-9"><title>Immunofluorescence</title><p>Immunofluorescence screenings were performed on HeLa cells as described before (<xref ref-type="bibr" rid="bib36">Nizak et al., 2005</xref>). (See the Appendix for more details).</p></sec><sec id="s4-10"><title>Transient transfection</title><p>Hela or HeLa S3 H2B-EGFP Cells cultured on coverslips were transfected according to the CaPO4 or jet prime procedure with 1 µg DNA per well (24 wells plate) or 10 µg DNA (10 cm2 diameter dish). Cells can be observed from 12 hr post-transfection on.</p></sec><sec id="s4-11"><title>Flow cytometry</title><p>For HER2 immunoassay, cell surface staining were performed in phosphate-buffered saline (PBS) supplemented with 1% SFV. 100 µL of supernatant (80 µL phages + 20 µL PBS/milk1%) were incubated on 1.10<sup>5</sup> cells for 1 hr on ice. Phage binding was detected by a 1:300 dilution of anti-M13 antibody (GE healthcare, France) for 1 hr on ice followed by a 1:1000 dilution of PE-conjugated anti-Mouse antibody (BD Bioscience, France) for 45 min. Samples were analyzed by flow cytometry on a FACSCalibur using CellQuest Pro software (BD Biosciences,France).</p><p>In the protein knockdown experiments, 48 hr after transfection, at least 10000 HeLa S3 H2B-GFP cells were analyzed on a MoFlo Astrios flow cytometer (Beckman Coulter France S.A.S) for their GFP fluorescence intensity. This fluorescence was analyzed in mCherry transfected cells and non transfected cells. Flow cytometry data were analyzed with Kaluza software (Beckman Coulter). 1 µM of proteasome inhibitor MG132 (Sigma-Aldrich) was used in the cell growth medium for 48 hr. Values reported represent median ± standard deviation (SD) of at least three independent experiments. p values were calculated with GraphPad Prism 6 (RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002798">SCR_002798</ext-link>) using a Student’s t test. **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001.</p></sec><sec id="s4-12"><title>Affinity measurement</title><p>All binding studies based on SPR technology were performed on BIAcore T200 optical biosensor instrument (RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_008424">SCR_008424</ext-link>, GE Healthcare). Capture of single domain Hs2dAb-6xHis was performed on a nitrilotriacetic acid (NTA) sensorchip in HBS-P+ buffer (10 mM Hepes pH 7.4, 150 mM NaCl, and 0.05% surfactant P20) (GE Healthcare). The four flow cells (FC) of the sensorchip were used: one (FC 1) to monitor nonspecific binding and to provide background corrections for analyses and the other three flow cells (FC 2, 3, and 4) containing immobilized Hs2dAb-6xHis for measurement.</p><p>For immobilization strategies, the four flow cells were loaded with nickel solution (10 μL/min for 60 s) in order to saturate the NTA surface with Ni2+ and an extra wash using running buffer containing 3 mM EDTA after the nickel injection. Each His-tagged hs2dAb in running buffer was injected in flow cells at a flow-rate of 10 μL/min. The total amount of immobilized hs2dAb-6xHis was 250–300 resonance units. (RUs; 1 RU corresponds approximately to 1 pg/mm2 of protein on the sensor chip). A Single-Cycle Kinetics (SCK) analysis to determine association (on-rates), dissociation (off-rates) and affinity constants (kon, koff and KD respectively) was carried out. SCK method prevents potential inaccuracy due to sensorchip regeneration between cycles which are necessary in the conventional multiple cycle kinetics (MCK) (<xref ref-type="bibr" rid="bib52">Trutnau, 2006</xref>). SCK binding parameters are evaluated for each injection according to the tools and fit models of the BIAevaluation software, giving similar values than MCK. As hs2dAb were smaller proteins than their respective antigens, hs2dAbs were captured on the sensorchip while the recombinant antigens were used as analytes. Analytes were injected sequentially with increased concentrations ranging between 3.125 nM to 50 nM in a single cycle without regeneration of the sensorship between injections. Binding parameters were obtained by fitting the overlaid sensorgrams with the 1:1. Langmuir binding model of the BIAevaluation software version 1.0.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The authors would like to acknowledge the help of the deep sequencing (ICGEx) and the imaging (PICT) platforms of the Institut Curie as well as the technical support of Aurélie Schneider, Selma Djender, and Alexis Arrial for the selection of anti-mCherry, anti-HER2 and anti-HP1α, Selma Djender and Anne Beugnet for the help in antibodies purification, Ahmed El Marjou for the production of recombinant HP1-Avitag and Anne-Laure Iscache for precious help in FACS experiments. We also would like to thank Yann Louault, Jean-Pierre Quivy and Christèle Maison for their help in characterizing anti-HP1 antibodies and Solene Hervé et Daniele Fachinetti for the characterization of the anti-p53 antbodies and the kind gift of the p53 shRNA expressing RPE-1 cell line.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf1"><p>SM: Co-inventor on a patent application (filled under ref: WO/2015/063331) that covers the hs2dAb scaffold and the commercial use of the library. The library has been licensed to Hybrigenics Service SA, which will perform screens on a fee-for-service basis. A consultant for Hybrigenics Service SA</p></fn><fn fn-type="conflict" id="conf3"><p>J-CR: Employed by, and a stockholder in, Hybrigenics Service SA</p></fn><fn fn-type="conflict" id="conf4"><p>AO: Co-inventor on a patent application (filled under ref: WO/2015/063331) that covers the hs2dAb scaffold and the commercial use of the library. The library has been licensed to Hybrigenics Service SA, which will perform screens on a fee-for-service basis</p></fn><fn fn-type="conflict" id="conf5"><p>FP: Co-inventor on a patent application (filled under ref: WO/2015/063331) that covers the hs2dAb scaffold and the commercial use of the library. The library has been licensed to Hybrigenics Service SA, which will perform screens on a fee-for-service basis. A consultant for Hybrigenics Service SA</p></fn><fn fn-type="conflict" id="conf2"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>SM, Carried out most of the experiments leading to the library construction, Designed and set up some of the screening approaches, Analyzed the data, Prepared the figures, Wrote the manuscript</p></fn><fn fn-type="con" id="con2"><p>NB, Designed and set up some of the screening approaches and conduced the protein knockdown experiments, Analyzed the data, Prepared the corresponding figures, Corrected the manuscript</p></fn><fn fn-type="con" id="con3"><p>VB, Carried out deep sequencing, Designed and carried out the NGS experiments, Analyzed the data and helped prepare the figure</p></fn><fn fn-type="con" id="con4"><p>LK, Designed and set up the GTP-RHO experiments, Analyzed the data, Prepared the figure</p></fn><fn fn-type="con" id="con5"><p>EL, Set-up the conditions and carried out the time-lapse imaging of living cells, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con6"><p>AdM, Executed some biochemical experiments, Analyzed the data, Acquisition of data</p></fn><fn fn-type="con" id="con7"><p>LL, Executed some biochemical experiments, Analyzed the data, Acquisition of data</p></fn><fn fn-type="con" id="con8"><p>J-CR, Helped for the construction of the library, Discussed the data, Conception and design, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con9"><p>GF, Supported the study, Corrected the manuscript, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con10"><p>AO, Contributed to the design and the supervision of the study, Analyzed the data, Acquisition of data, Wrote the manuscript</p></fn><fn fn-type="con" id="con11"><p>FP, Designed, supervised and supported the project, Wrote the article, Analysis and interpretation of data</p></fn></fn-group></sec><ref-list><title>References </title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartunek</surname><given-names>J</given-names></name><name><surname>Barbato</surname><given-names>E</given-names></name><name><surname>Heyndrickx</surname><given-names>G</given-names></name><name><surname>Vanderheyden</surname><given-names>M</given-names></name><name><surname>Wijns</surname><given-names>W</given-names></name><name><surname>Holz</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Novel antiplatelet agents: ALX-0081, a Nanobody directed towards von Willebrand factor</article-title><source>Journal of Cardiovascular Translational Research</source><volume>6</volume><fpage>355</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1007/s12265-012-9435-y</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernard</surname><given-names>P</given-names></name><name><surname>Gabant</surname><given-names>P</given-names></name><name><surname>Bahassi</surname><given-names>EM</given-names></name><name><surname>Couturier</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Positive-selection vectors using the F plasmid ccdB killer gene</article-title><source>Gene</source><volume>148</volume><fpage>71</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/0378-1119(94)90235-6</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Böldicke</surname><given-names>T</given-names></name><name><surname>Weber</surname><given-names>H</given-names></name><name><surname>Mueller</surname><given-names>PP</given-names></name><name><surname>Barleon</surname><given-names>B</given-names></name><name><surname>Bernal</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Novel highly efficient intrabody mediates complete inhibition of cell surface expression of the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR)</article-title><source>Journal of Immunological Methods</source><volume>300</volume><fpage>146</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2005.03.007</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caussinus</surname><given-names>E</given-names></name><name><surname>Kanca</surname><given-names>O</given-names></name><name><surname>Affolter</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fluorescent fusion protein knockout mediated by anti-GFP nanobody</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>19</volume><fpage>117</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1038/nsmb.2180</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chinestra</surname><given-names>P</given-names></name><name><surname>Lajoie-Mazenc</surname><given-names>I</given-names></name><name><surname>Faye</surname><given-names>JC</given-names></name><name><surname>Favre</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Use of phage display for the identification of molecular sensors specific for activated Rho</article-title><source>Methods in Molecular Biology</source><volume>827</volume><fpage>283</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1007/978-1-61779-442-1_19</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christ</surname><given-names>D</given-names></name><name><surname>Famm</surname><given-names>K</given-names></name><name><surname>Winter</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Repertoires of aggregation-resistant human antibody domains</article-title><source>Protein Engineering Design and Selection</source><volume>20</volume><fpage>413</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1093/protein/gzm037</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimitrov</surname><given-names>A</given-names></name><name><surname>Quesnoit</surname><given-names>M</given-names></name><name><surname>Moutel</surname><given-names>S</given-names></name><name><surname>Cantaloube</surname><given-names>I</given-names></name><name><surname>Poüs</surname><given-names>C</given-names></name><name><surname>Perez</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Detection of GTP-tubulin conformation in vivo reveals a role for GTP remnants in microtubule rescues</article-title><source>Science</source><volume>322</volume><fpage>1353</fpage><lpage>1356</lpage><pub-id pub-id-type="doi">10.1126/science.1165401</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Even-Desrumeaux</surname><given-names>K</given-names></name><name><surname>Chames</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Phage display and selections on cells</article-title><source>Methods in Molecular Biology</source><volume>907</volume><fpage>225</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1007/978-1-61779-974-7_12</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Even-Desrumeaux</surname><given-names>K</given-names></name><name><surname>Nevoltris</surname><given-names>D</given-names></name><name><surname>Lavaut</surname><given-names>MN</given-names></name><name><surname>Alim</surname><given-names>K</given-names></name><name><surname>Borg</surname><given-names>JP</given-names></name><name><surname>Audebert</surname><given-names>S</given-names></name><name><surname>Kerfelec</surname><given-names>B</given-names></name><name><surname>Baty</surname><given-names>D</given-names></name><name><surname>Chames</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Masked selection: a straightforward and flexible approach for the selection of binders against specific epitopes and differentially expressed proteins by phage display</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>13</volume><fpage>653</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1074/mcp.O112.025486</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goffinet</surname><given-names>M</given-names></name><name><surname>Chinestra</surname><given-names>P</given-names></name><name><surname>Lajoie-Mazenc</surname><given-names>I</given-names></name><name><surname>Medale-Giamarchi</surname><given-names>C</given-names></name><name><surname>Favre</surname><given-names>G</given-names></name><name><surname>Faye</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Identification of a GTP-bound Rho specific scFv molecular sensor by phage display selection</article-title><source>BMC Biotechnology</source><volume>8</volume><fpage>34</fpage><pub-id pub-id-type="doi">10.1186/1472-6750-8-34</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldman</surname><given-names>ER</given-names></name><name><surname>Anderson</surname><given-names>GP</given-names></name><name><surname>Liu</surname><given-names>JL</given-names></name><name><surname>Delehanty</surname><given-names>JB</given-names></name><name><surname>Sherwood</surname><given-names>LJ</given-names></name><name><surname>Osborn</surname><given-names>LE</given-names></name><name><surname>Cummins</surname><given-names>LB</given-names></name><name><surname>Hayhurst</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Facile generation of heat-stable antiviral and antitoxin single domain antibodies from a semisynthetic llama library</article-title><source>Analytical Chemistry</source><volume>78</volume><fpage>8245</fpage><lpage>8255</lpage><pub-id pub-id-type="doi">10.1021/ac0610053</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>AS</given-names></name><name><surname>Avila</surname><given-names>D</given-names></name><name><surname>Hughes</surname><given-names>M</given-names></name><name><surname>Hughes</surname><given-names>A</given-names></name><name><surname>McKinney</surname><given-names>EC</given-names></name><name><surname>Flajnik</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks</article-title><source>Nature</source><volume>374</volume><fpage>168</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1038/374168a0</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guglielmi</surname><given-names>L</given-names></name><name><surname>Denis</surname><given-names>V</given-names></name><name><surname>Vezzio-Vie</surname><given-names>N</given-names></name><name><surname>Bec</surname><given-names>N</given-names></name><name><surname>Dariavach</surname><given-names>P</given-names></name><name><surname>Larroque</surname><given-names>C</given-names></name><name><surname>Martineau</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Selection for intrabody solubility in mammalian cells using GFP fusions</article-title><source>Protein Engineering Design and Selection</source><volume>24</volume><fpage>873</fpage><lpage>881</lpage><pub-id pub-id-type="doi">10.1093/protein/gzr049</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamers-Casterman</surname><given-names>C</given-names></name><name><surname>Atarhouch</surname><given-names>T</given-names></name><name><surname>Muyldermans</surname><given-names>S</given-names></name><name><surname>Robinson</surname><given-names>G</given-names></name><name><surname>Hamers</surname><given-names>C</given-names></name><name><surname>Songa</surname><given-names>EB</given-names></name><name><surname>Bendahman</surname><given-names>N</given-names></name><name><surname>Hamers</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Naturally occurring antibodies devoid of light chains</article-title><source>Nature</source><volume>363</volume><fpage>446</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1038/363446a0</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haque</surname><given-names>A</given-names></name><name><surname>Andersen</surname><given-names>JN</given-names></name><name><surname>Salmeen</surname><given-names>A</given-names></name><name><surname>Barford</surname><given-names>D</given-names></name><name><surname>Tonks</surname><given-names>NK</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Conformation-sensing antibodies stabilize the oxidized form of PTP1B and inhibit its phosphatase activity</article-title><source>Cell</source><volume>147</volume><fpage>185</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.08.036</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holz</surname><given-names>J-B</given-names></name><name><surname>Sargentini-Maier</surname><given-names>L</given-names></name><name><surname>De Bruyn</surname><given-names>S</given-names></name><name><surname>Gachalyi</surname><given-names>B</given-names></name><name><surname>Udvaros</surname><given-names>I</given-names></name><name><surname>Rojkovich</surname><given-names>B</given-names></name><name><surname>Bruk</surname><given-names>S</given-names></name><name><surname>Sramek</surname><given-names>P</given-names></name><name><surname>Korkosz</surname><given-names>M</given-names></name><name><surname>Krause</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>OP0043 Twenty-four weeks of treatment with a novel anti-IL-6 receptor nanobody (R) (ALX-0061) resulted in 84% ACR20 improvement and 58% DAS28 remission in a phase I/Ii study in RA</article-title><source>Annals of the Rheumatic Diseases</source><volume>72</volume><fpage>A64</fpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2013-eular.248</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoogenboom</surname><given-names>HR</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Selecting and screening recombinant antibody libraries</article-title><source>Nature Biotechnology</source><volume>23</volume><fpage>1105</fpage><lpage>1116</lpage><pub-id pub-id-type="doi">10.1038/nbt1126</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jobling</surname><given-names>SA</given-names></name><name><surname>Jarman</surname><given-names>C</given-names></name><name><surname>Teh</surname><given-names>MM</given-names></name><name><surname>Holmberg</surname><given-names>N</given-names></name><name><surname>Blake</surname><given-names>C</given-names></name><name><surname>Verhoeyen</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Immunomodulation of enzyme function in plants by single-domain antibody fragments</article-title><source>Nature Biotechnology</source><volume>21</volume><fpage>77</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1038/nbt772</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname><given-names>SN</given-names></name><name><surname>Butler</surname><given-names>DC</given-names></name><name><surname>Messer</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies</article-title><source>mAbs</source><volume>4</volume><fpage>686</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.4161/mabs.21696</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaiser</surname><given-names>PD</given-names></name><name><surname>Maier</surname><given-names>J</given-names></name><name><surname>Traenkle</surname><given-names>B</given-names></name><name><surname>Emele</surname><given-names>F</given-names></name><name><surname>Rothbauer</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Recent progress in generating intracellular functional antibody fragments to target and trace cellular components in living cells</article-title><source>Biochimica Et Biophysica Acta (BBA) - Proteins and Proteomics</source><volume>1844</volume><fpage>1933</fpage><lpage>1942</lpage><pub-id pub-id-type="doi">10.1016/j.bbapap.2014.04.019</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirchhofer</surname><given-names>A</given-names></name><name><surname>Helma</surname><given-names>J</given-names></name><name><surname>Schmidthals</surname><given-names>K</given-names></name><name><surname>Frauer</surname><given-names>C</given-names></name><name><surname>Cui</surname><given-names>S</given-names></name><name><surname>Karcher</surname><given-names>A</given-names></name><name><surname>Pellis</surname><given-names>M</given-names></name><name><surname>Muyldermans</surname><given-names>S</given-names></name><name><surname>Casas-Delucchi</surname><given-names>CS</given-names></name><name><surname>Cardoso</surname><given-names>MC</given-names></name><name><surname>Leonhardt</surname><given-names>H</given-names></name><name><surname>Hopfner</surname><given-names>KP</given-names></name><name><surname>Rothbauer</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Modulation of protein properties in living cells using nanobodies</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>17</volume><fpage>133</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1038/nsmb.1727</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>H</given-names></name><name><surname>Gräfe</surname><given-names>N</given-names></name><name><surname>Schiess</surname><given-names>R</given-names></name><name><surname>Plückthun</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Direct selection of antibodies from complex libraries with the protein fragment complementation assay</article-title><source>Journal of Molecular Biology</source><volume>357</volume><fpage>427</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2005.12.043</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koide</surname><given-names>S</given-names></name><name><surname>Koide</surname><given-names>A</given-names></name><name><surname>Lipovšek</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Target-binding proteins based on the 10th human fibronectin type III domain (¹⁰Fn3)</article-title><source>Methods in Enzymology</source><volume>503</volume><fpage>135</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-396962-0.00006-9</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CM</given-names></name><name><surname>Iorno</surname><given-names>N</given-names></name><name><surname>Sierro</surname><given-names>F</given-names></name><name><surname>Christ</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Selection of human antibody fragments by phage display</article-title><source>Nature Protocols</source><volume>2</volume><fpage>3001</fpage><lpage>3008</lpage><pub-id pub-id-type="doi">10.1038/nprot.2007.448</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lobato</surname><given-names>MN</given-names></name><name><surname>Rabbitts</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Intracellular antibodies and challenges facing their use as therapeutic agents</article-title><source>Trends in Molecular Medicine</source><volume>9</volume><fpage>390</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1016/S1471-4914(03)00163-1</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandrup</surname><given-names>OA</given-names></name><name><surname>Friis</surname><given-names>NA</given-names></name><name><surname>Lykkemark</surname><given-names>S</given-names></name><name><surname>Just</surname><given-names>J</given-names></name><name><surname>Kristensen</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A novel heavy domain antibody library with functionally optimized complementarity determining regions</article-title><source>PLoS One</source><volume>8</volume><elocation-id>e76834</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0076834</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marks</surname><given-names>JD</given-names></name><name><surname>Hoogenboom</surname><given-names>HR</given-names></name><name><surname>Bonnert</surname><given-names>TP</given-names></name><name><surname>McCafferty</surname><given-names>J</given-names></name><name><surname>Griffiths</surname><given-names>AD</given-names></name><name><surname>Winter</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>By-passing immunization</article-title><source>Journal of Molecular Biology</source><volume>222</volume><fpage>581</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1016/0022-2836(91)90498-U</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayer</surname><given-names>T</given-names></name><name><surname>Meyer</surname><given-names>M</given-names></name><name><surname>Janning</surname><given-names>A</given-names></name><name><surname>Schiedel</surname><given-names>AC</given-names></name><name><surname>Barnekow</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>A mutant form of the rho protein can restore stress fibers and adhesion plaques in v-src transformed fibroblasts</article-title><source>Oncogene</source><volume>18</volume><fpage>2117</fpage><lpage>2128</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1202537</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melchionna</surname><given-names>T</given-names></name><name><surname>Cattaneo</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A protein silencing switch by ligand-induced proteasome-targeting intrabodies</article-title><source>Journal of Molecular Biology</source><volume>374</volume><fpage>641</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2007.09.053</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mikhaylova</surname><given-names>M</given-names></name><name><surname>Cloin</surname><given-names>BM</given-names></name><name><surname>Finan</surname><given-names>K</given-names></name><name><surname>van den Berg</surname><given-names>R</given-names></name><name><surname>Teeuw</surname><given-names>J</given-names></name><name><surname>Kijanka</surname><given-names>MM</given-names></name><name><surname>Sokolowski</surname><given-names>M</given-names></name><name><surname>Katrukha</surname><given-names>EA</given-names></name><name><surname>Maidorn</surname><given-names>M</given-names></name><name><surname>Opazo</surname><given-names>F</given-names></name><name><surname>Moutel</surname><given-names>S</given-names></name><name><surname>Vantard</surname><given-names>M</given-names></name><name><surname>Perez</surname><given-names>F</given-names></name><name><surname>van Bergen en Henegouwen</surname><given-names>PM</given-names></name><name><surname>Hoogenraad</surname><given-names>CC</given-names></name><name><surname>Ewers</surname><given-names>H</given-names></name><name><surname>Kapitein</surname><given-names>LC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Resolving bundled microtubules using anti-tubulin nanobodies</article-title><source>Nature Communications</source><volume>6</volume><fpage>7933</fpage><pub-id pub-id-type="doi">10.1038/ncomms8933</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monegal</surname><given-names>A</given-names></name><name><surname>Olichon</surname><given-names>A</given-names></name><name><surname>Bery</surname><given-names>N</given-names></name><name><surname>Filleron</surname><given-names>T</given-names></name><name><surname>Favre</surname><given-names>G</given-names></name><name><surname>de Marco</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Single domain antibodies with VH hallmarks are positively selected during panning of llama (Lama glama) naïve libraries</article-title><source>Developmental and Comparative Immunology</source><volume>36</volume><fpage>150</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/j.dci.2011.06.016</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moutel</surname><given-names>S</given-names></name><name><surname>El Marjou</surname><given-names>A</given-names></name><name><surname>Vielemeyer</surname><given-names>O</given-names></name><name><surname>Nizak</surname><given-names>C</given-names></name><name><surname>Benaroch</surname><given-names>P</given-names></name><name><surname>Dübel</surname><given-names>S</given-names></name><name><surname>Perez</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A multi-Fc-species system for recombinant antibody production</article-title><source>BMC Biotechnology</source><volume>9</volume><elocation-id>14</elocation-id><pub-id pub-id-type="doi">10.1186/1472-6750-9-14</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muyldermans</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Nanobodies: natural single-domain antibodies</article-title><source>Annual Review of Biochemistry</source><volume>82</volume><fpage>775</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-063011-092449</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nizak</surname><given-names>C</given-names></name><name><surname>Monier</surname><given-names>S</given-names></name><name><surname>del Nery</surname><given-names>E</given-names></name><name><surname>Moutel</surname><given-names>S</given-names></name><name><surname>Goud</surname><given-names>B</given-names></name><name><surname>Perez</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2003">2003a</year><article-title>Recombinant antibodies to the small GTPase Rab6 as conformation sensors</article-title><source>Science</source><volume>300</volume><fpage>984</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1126/science.1083911</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nizak</surname><given-names>C</given-names></name><name><surname>Martin-Lluesma</surname><given-names>S</given-names></name><name><surname>Moutel</surname><given-names>S</given-names></name><name><surname>Roux</surname><given-names>A</given-names></name><name><surname>Kreis</surname><given-names>TE</given-names></name><name><surname>Goud</surname><given-names>B</given-names></name><name><surname>Perez</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2003">2003b</year><article-title>Recombinant antibodies against subcellular fractions used to track endogenous Golgi protein dynamics in vivo</article-title><source>Traffic</source><volume>4</volume><fpage>739</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1034/j.1600-0854.2003.00132.x</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nizak</surname><given-names>C</given-names></name><name><surname>Moutel</surname><given-names>S</given-names></name><name><surname>Goud</surname><given-names>B</given-names></name><name><surname>Perez</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Selection and application of recombinant antibodies as sensors of rab protein conformation</article-title><source>Methods in Enzymology</source><volume>403</volume><fpage>135</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/S0076-6879(05)03012-0</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olichon</surname><given-names>A</given-names></name><name><surname>Surrey</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Selection of genetically encoded fluorescent single domain antibodies engineered for efficient expression in Escherichia coli</article-title><source>Journal of Biological Chemistry</source><volume>282</volume><fpage>36314</fpage><lpage>36320</lpage><pub-id pub-id-type="doi">10.1074/jbc.M704908200</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olichon</surname><given-names>A</given-names></name><name><surname>Schweizer</surname><given-names>D</given-names></name><name><surname>Muyldermans</surname><given-names>S</given-names></name><name><surname>de Marco</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007a</year><article-title>Heating as a rapid purification method for recovering correctly-folded thermotolerant VH and VHH domains</article-title><source>BMC Biotechnology</source><volume>7</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/1472-6750-7-7</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olichon</surname><given-names>A</given-names></name><name><surname>Elachouri</surname><given-names>G</given-names></name><name><surname>Baricault</surname><given-names>L</given-names></name><name><surname>Delettre</surname><given-names>C</given-names></name><name><surname>Belenguer</surname><given-names>P</given-names></name><name><surname>Lenaers</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2007">2007b</year><article-title>OPA1 alternate splicing uncouples an evolutionary conserved function in mitochondrial fusion from a vertebrate restricted function in apoptosis</article-title><source>Cell Death and Differentiation</source><volume>14</volume><fpage>682</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4402048</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pellis</surname><given-names>M</given-names></name><name><surname>Pardon</surname><given-names>E</given-names></name><name><surname>Zolghadr</surname><given-names>K</given-names></name><name><surname>Rothbauer</surname><given-names>U</given-names></name><name><surname>Vincke</surname><given-names>C</given-names></name><name><surname>Kinne</surname><given-names>J</given-names></name><name><surname>Dierynck</surname><given-names>I</given-names></name><name><surname>Hertogs</surname><given-names>K</given-names></name><name><surname>Leonhardt</surname><given-names>H</given-names></name><name><surname>Messens</surname><given-names>J</given-names></name><name><surname>Muyldermans</surname><given-names>S</given-names></name><name><surname>Conrath</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A bacterial-two-hybrid selection system for one-step isolation of intracellularly functional Nanobodies</article-title><source>Archives of Biochemistry and Biophysics</source><volume>526</volume><fpage>114</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/j.abb.2012.04.023</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prassler</surname><given-names>J</given-names></name><name><surname>Thiel</surname><given-names>S</given-names></name><name><surname>Pracht</surname><given-names>C</given-names></name><name><surname>Polzer</surname><given-names>A</given-names></name><name><surname>Peters</surname><given-names>S</given-names></name><name><surname>Bauer</surname><given-names>M</given-names></name><name><surname>Nörenberg</surname><given-names>S</given-names></name><name><surname>Stark</surname><given-names>Y</given-names></name><name><surname>Kölln</surname><given-names>J</given-names></name><name><surname>Popp</surname><given-names>A</given-names></name><name><surname>Urlinger</surname><given-names>S</given-names></name><name><surname>Enzelberger</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>HuCAL PLATINUM, a synthetic Fab library optimized for sequence diversity and superior performance in mammalian expression systems</article-title><source>Journal of Molecular Biology</source><volume>413</volume><fpage>261</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2011.08.012</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>XD</given-names></name><name><surname>Kiosses</surname><given-names>WB</given-names></name><name><surname>Schwartz</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton</article-title><source>The EMBO Journal</source><volume>18</volume><fpage>578</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1093/emboj/18.3.578</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridley</surname><given-names>AJ</given-names></name><name><surname>Hall</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors</article-title><source>Cell</source><volume>70</volume><fpage>389</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1016/0962-8924(92)90173-K</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothbauer</surname><given-names>U</given-names></name><name><surname>Zolghadr</surname><given-names>K</given-names></name><name><surname>Tillib</surname><given-names>S</given-names></name><name><surname>Nowak</surname><given-names>D</given-names></name><name><surname>Schermelleh</surname><given-names>L</given-names></name><name><surname>Gahl</surname><given-names>A</given-names></name><name><surname>Backmann</surname><given-names>N</given-names></name><name><surname>Conrath</surname><given-names>K</given-names></name><name><surname>Muyldermans</surname><given-names>S</given-names></name><name><surname>Cardoso</surname><given-names>MC</given-names></name><name><surname>Leonhardt</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Targeting and tracing antigens in live cells with fluorescent nanobodies</article-title><source>Nature Methods</source><volume>3</volume><fpage>887</fpage><lpage>889</lpage><pub-id pub-id-type="doi">10.1038/nmeth953</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saerens</surname><given-names>D</given-names></name><name><surname>Pellis</surname><given-names>M</given-names></name><name><surname>Loris</surname><given-names>R</given-names></name><name><surname>Pardon</surname><given-names>E</given-names></name><name><surname>Dumoulin</surname><given-names>M</given-names></name><name><surname>Matagne</surname><given-names>A</given-names></name><name><surname>Wyns</surname><given-names>L</given-names></name><name><surname>Muyldermans</surname><given-names>S</given-names></name><name><surname>Conrath</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Identification of a universal VHH framework to graft non-canonical antigen-binding loops of camel single-domain antibodies</article-title><source>Journal of Molecular Biology</source><volume>352</volume><fpage>597</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2005.07.038</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>I</given-names></name><name><surname>Edl</surname><given-names>J</given-names></name><name><surname>Biswas</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>PC</given-names></name><name><surname>Mernaugh</surname><given-names>R</given-names></name><name><surname>Arteaga</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Proapoptotic activity of cell-permeable anti-Akt single-chain antibodies</article-title><source>Cancer Research</source><volume>65</volume><fpage>2815</fpage><lpage>2824</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-2898</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silljé</surname><given-names>HH</given-names></name><name><surname>Nagel</surname><given-names>S</given-names></name><name><surname>Körner</surname><given-names>R</given-names></name><name><surname>Nigg</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>HURP is a Ran-importin beta-regulated protein that stabilizes kinetochore microtubules in the vicinity of chromosomes</article-title><source>Current Biology</source><volume>16</volume><fpage>731</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2006.02.070</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stocks</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Intrabodies as drug discovery tools and therapeutics</article-title><source>Current Opinion in Chemical Biology</source><volume>9</volume><fpage>359</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1016/j.cbpa.2005.06.003</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamaskovic</surname><given-names>R</given-names></name><name><surname>Simon</surname><given-names>M</given-names></name><name><surname>Stefan</surname><given-names>N</given-names></name><name><surname>Schwill</surname><given-names>M</given-names></name><name><surname>Plückthun</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Designed ankyrin repeat proteins (DARPins) from research to therapy</article-title><source>Methods in Enzymology</source><volume>503</volume><fpage>101</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-396962-0.00005-7</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Williams</surname><given-names>RL</given-names></name><name><surname>Rabbitts</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS</article-title><source>The EMBO Journal</source><volume>26</volume><fpage>3250</fpage><lpage>3259</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7601744</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Rabbitts</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Protocol for the selection of single-domain antibody fragments by third generation intracellular antibody capture</article-title><source>Nature Protocols</source><volume>5</volume><fpage>67</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1038/nprot.2009.199</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trutnau</surname><given-names>HH</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>New multi-step kinetics using common affinity biosensors saves time and sample at full access to kinetics and concentration</article-title><source>Journal of Biotechnology</source><volume>124</volume><fpage>191</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2006.01.006</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vercruysse</surname><given-names>T</given-names></name><name><surname>Pardon</surname><given-names>E</given-names></name><name><surname>Vanstreels</surname><given-names>E</given-names></name><name><surname>Steyaert</surname><given-names>J</given-names></name><name><surname>Daelemans</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>An intrabody based on a llama single-domain antibody targeting the N-terminal alpha-helical multimerization domain of HIV-1 rev prevents viral production</article-title><source>Journal of Biological Chemistry</source><volume>285</volume><fpage>21768</fpage><lpage>21780</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.112490</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vielemeyer</surname><given-names>O</given-names></name><name><surname>Yuan</surname><given-names>H</given-names></name><name><surname>Moutel</surname><given-names>S</given-names></name><name><surname>Saint-Fort</surname><given-names>R</given-names></name><name><surname>Tang</surname><given-names>D</given-names></name><name><surname>Nizak</surname><given-names>C</given-names></name><name><surname>Goud</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Perez</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Direct selection of monoclonal phosphospecific antibodies without prior phosphoamino acid mapping</article-title><source>Journal of Biological Chemistry</source><volume>284</volume><fpage>20791</fpage><lpage>20795</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.008730</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wesolowski</surname><given-names>J</given-names></name><name><surname>Alzogaray</surname><given-names>V</given-names></name><name><surname>Reyelt</surname><given-names>J</given-names></name><name><surname>Unger</surname><given-names>M</given-names></name><name><surname>Juarez</surname><given-names>K</given-names></name><name><surname>Urrutia</surname><given-names>M</given-names></name><name><surname>Cauerhff</surname><given-names>A</given-names></name><name><surname>Danquah</surname><given-names>W</given-names></name><name><surname>Rissiek</surname><given-names>B</given-names></name><name><surname>Scheuplein</surname><given-names>F</given-names></name><name><surname>Schwarz</surname><given-names>N</given-names></name><name><surname>Adriouch</surname><given-names>S</given-names></name><name><surname>Boyer</surname><given-names>O</given-names></name><name><surname>Seman</surname><given-names>M</given-names></name><name><surname>Licea</surname><given-names>A</given-names></name><name><surname>Serreze</surname><given-names>DV</given-names></name><name><surname>Goldbaum</surname><given-names>FA</given-names></name><name><surname>Haag</surname><given-names>F</given-names></name><name><surname>Koch-Nolte</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Single domain antibodies: promising experimental and therapeutic tools in infection and immunity</article-title><source>Medical Microbiology and Immunology</source><volume>198</volume><fpage>157</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1007/s00430-009-0116-7</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wörn</surname><given-names>A</given-names></name><name><surname>Plückthun</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Different equilibrium stability behavior of ScFv fragments: identification, classification, and improvement by protein engineering</article-title><source>Biochemistry</source><volume>38</volume><fpage>8739</fpage><lpage>8750</lpage><pub-id pub-id-type="doi">10.1021/bi9902079</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhai</surname><given-names>W</given-names></name><name><surname>Glanville</surname><given-names>J</given-names></name><name><surname>Fuhrmann</surname><given-names>M</given-names></name><name><surname>Mei</surname><given-names>L</given-names></name><name><surname>Ni</surname><given-names>I</given-names></name><name><surname>Sundar</surname><given-names>PD</given-names></name><name><surname>Van Blarcom</surname><given-names>T</given-names></name><name><surname>Abdiche</surname><given-names>Y</given-names></name><name><surname>Lindquist</surname><given-names>K</given-names></name><name><surname>Strohner</surname><given-names>R</given-names></name><name><surname>Telman</surname><given-names>D</given-names></name><name><surname>Cappuccilli</surname><given-names>G</given-names></name><name><surname>Finlay</surname><given-names>WJ</given-names></name><name><surname>Van den Brulle</surname><given-names>J</given-names></name><name><surname>Cox</surname><given-names>DR</given-names></name><name><surname>Pons</surname><given-names>J</given-names></name><name><surname>Rajpal</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Synthetic antibodies designed on natural sequence landscapes</article-title><source>Journal of Molecular Biology</source><volume>412</volume><fpage>55</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2011.07.018</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zolghadr</surname><given-names>K</given-names></name><name><surname>Mortusewicz</surname><given-names>O</given-names></name><name><surname>Rothbauer</surname><given-names>U</given-names></name><name><surname>Kleinhans</surname><given-names>R</given-names></name><name><surname>Goehler</surname><given-names>H</given-names></name><name><surname>Wanker</surname><given-names>EE</given-names></name><name><surname>Cardoso</surname><given-names>MC</given-names></name><name><surname>Leonhardt</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A fluorescent two-hybrid assay for direct visualization of protein interactions in living cells</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>7</volume><fpage>2279</fpage><lpage>2287</lpage><pub-id pub-id-type="doi">10.1074/mcp.M700548-MCP200</pub-id></element-citation></ref></ref-list><app-group><app id="app1"><title>Appendix</title><boxed-text><sec id="s24" sec-type="appendix"><title>Supplementary methods</title><sec id="s25"><title>Plasmids and cloning</title><p>myc-Tags synthetic gene inserted in pHen2 vector: NotI-HHHHHHGAAEQKLISEEDLNGAAEQKLISEEDLNGAAEQKLISEEDLNGAA*(tag)-pIII-BamHI.</p><p>p53: TP53 hMDM2 interacting domain (aa 1 to aa 83 ref NP_000537) has been cloned in pEB23, a pEMBL41 derivative in which MBP have been replaced by SNAP tag (New England Biolabs France). Fusion protein has been purified using Talon resin (Takara - Clontech) from 100 mL LB culture induced for 2 hr at 37°C with 1 mM IPTG. One µM of purified protein was biotinylated using 1 µM of SNAP-biotin (S9110S, New England Biolabs) for 2 hr at 25°C and purified by G50.</p><sec id="s26"><title>Production of RHO GTPases amino terminal fusion construct.</title><p>Chitin binding domain (CBD) was amplified from pTYB2 (New England Biolabs) using the following oligos: CBDAgeIfw 5’-TACATTCAACCGGTCGCCACCATGACAAATCCTGGTGTATCCGCTTGG-3’ and CBDTevRev 5’-CGAACTGAAAGTACAGATTCTCGCTGCCTTGAAGCTGCCA CAAGGCAGG-3’. RHOB cDNA was amplified from pGST-RHOBQ63L with the upstream primer TevAccRHOB Fw 5’-GAGAATCTGT ACTTTCAGTT CGGCGGTACC GCGGCCATCC GCAAGAAGCT GG-3’. A single step PCR created the CBDtevRHOB fusion product that was cloned in a pEYFP-RHOB (1) after digestion AgeI /BamHI, creating the pCBD-RHOB mammalian expression vector, RHOB was further exchanged by RHOAQ63L or RHOA T19N using Acc65I/BamHI cloning sites. The amino terminal CBD tag was replaced by either a dual Streptag (2S) or the superfolder GFP using AgeI and KpnI cloning sites. A 2S tag corresponding to a tandem repeat of the streptagII (IBA) separated by a flexible linker was gene synthesized (Geneart - ThermoFisher Biosciences). Superfolder GFP was amplified from pSuperfolder (gift from Cabantous S) using the AgeISFGFPFw 5’-AATGACATACCGGTCGCCACCATGGTGAGCAAGGGCGAGGAG-3’ and SFGFPKpnIRev 5’-AAGTCAGGTACCGCCACCGCTGCCGCCACCCTTGTACAGCTCGTCCATGCCG-3’. The constructs pCBD-RHOA N19 or L63 were used in co-immunoprecipitation with GFP-hsdAb experiments, and the pSFGFP-RHOA N19 or L63 mutants were used to monitor H12 immunofluorescence experiments.</p><p>A CBS-2S dual tag was PCR amplified and cloned at the NotI site downstream of hs2dAb in pHEN6 vector, in order to produce pHEN- hs2dAb-CBD2S-6his. Purified hs2dAbs from this construct were used in RHOA pull down experiments.</p></sec><sec id="s27"><title>Construction of Fbox/NoFbox- hs2dAb-6Hismyc-IRES-MTS-FP expressing vectors.</title><p>A PCR was performed to extract the Fbox and noFbox sequences from the plasmids NSlmb-VHHGFP4 and NSnoFbox-VHHGFP4 using BspHIFboxFw (5’ GTTCATGTCATGATGAAAAT GGAGACTG ACAAAATAATGG 3’) and FboxNcoRev (5’ CAAGATCCCATGGCGAGGTGGCGGCCAGTCCGCCAGTTG 3’) primers. These fragments were inserted in the p-Ib plasmid (intrabodies expression vector with CMV promotor) by digesting with BspHI and NcoI. The vectors pIB-VHHGFP4, pIb-Fbox-VHHGFP4 and pIb-NoFboxVHHGFP4 were obtained. Then IRES-MTS-fluorescent protein was inserted by PCR downstream of the VHH. IRES was amplified from pCCEY (<xref ref-type="bibr" rid="bib39">Olichon et al., 2007b</xref>) with insertion of flanking downstream restriction sites AgeI, NheI and Acc65I. Then a mitochondrial targeting sequence (MTS) from subunit VIII of human cytochrome c oxidase (pEYFP-MTS, Takara - Clontech) was inserted between NheI / AgeI, followed by mCherry between AgeI / Acc65I, thus creating the p-F-Ib_IRES_mito-mCherry; p-noF-Ib_IRES_mito-mCherry; p-Ib_IRES_mito-mCherry in which any hs2dAb can be inserted by NcoI and NotI cloning sites.</p></sec></sec><sec id="s28"><title>CAT filter assay</title><p>Previously selected VHHs from naïve or immune libraries were subcloned into pAOCAT (<xref ref-type="bibr" rid="bib31">Monegal et al., 2012</xref>) using the NcoI and NotI restriction sites. Chloramphenicol resistance assay was performed using BL21(DE3) cells transformed with the pAOCAT-VHH fusion constructs. Bacteria were used for inoculating 500 µL of LB containing kanamycin (35 µg/mL) and glucose (0.2%) and were grown at 37°C until OD<sub>600</sub> was 0.8. The cytoplasmic expression of the VHH-CAT-fusion proteins was induced for 2 hr by the addition of 0.2 mM IPTG. At the end of the induction period, bacteria aliquots of 4 µL were plated on LB-agar plates containing IPTG (0.1 mM) and increasing chloramphenicol concentrations ranging from 0 to 500 µg/mL. Bacteria were incubated at 30°C for 20 hr before quantification of the colony formation. The resistance level was evaluated according to the colony growth rate at the different chloramphenicol concentrations. Several VHHs that were giving colonies up to 500 µg/mL were compared to previously characterized intrabodies raised against GFP (nb GFP4) or Lamin (Lam) obtained by gene synthesis (GeneArt - ThermoFisher BioSciences) as well as to a thermostable VHH Re3. Liquid culture induced as above during 2 hr were diluted by serial dilution and 10 µL of each dilution were spotted on agar plates containing 250 µg/mL chloramphenicol (Cam) and 35 µg/mL kanamycin and incubated at 30°C for 20 hr. Colony were imaged using ChemiDoc MP imaging system (Biorad France).</p><p>The D10 clone was further subcloned into the pHEN6 expression vector, leading to a periplasmic expression higher than 5 mg/L of culture in E coli Xl1blue strain.</p></sec><sec id="s29"><title>Library construction</title><p>The amino acids residues chosen for each position of the synthetic CDR loops were determined after analyzing the natural diversity existing at each position on natural VHH and following the rules indicated bellow (see <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref> for diversity comparison between natural VHH and hs2dAb)</p><p>at CDR1 position 1: Y, R, S, T, F, G, A, or D [Y,S, F were the most frequent amino acid]</p><p>at CDR1 position 2: Y, S, T, F, G, T, or T [T was the most frequent amino acid so we imposed a 3 fold higher stoichiometry for T at that position]</p><p>at CDR1 position 3: Y, S, S, S F, or W [S was the most frequent amino acid so we imposed a 3 fold higher stoichiometry for T at that position]</p><p>at CDR1 position 4: Y, R, S, T, F, G, A, W, D, E, K or N [natural diversity respected while avoiding hydrophobic residues]</p><p>at CDR1 position 5: S, T, F, G, A, W, D, E, N, I, H, R, Q, or L [natural diversity respected. Because the frequency of hydrophobic I was high at this position in natural VHH, some hydrophobic amino acids were accepted]</p><p>at CDR1 position 6: S, T, Y, D, or E [S, T, and Y were the most frequently found amino acids in natural VHH]</p><p>at CDR1 position 7: S, T, G, A, D, E, N, I, or V [a high frequency of hydrophobic I or V was observed in natural VHH but their proportion was reduced here by adding polar residues]</p><p>at CDR2 position 1: R, S, F, G, A, W, D, E, or Y [D and E were added to help for solubility and W for specific interaction in hydrophobic pockets]</p><p>at CDR2 position 2: S, T, F, G, A, W, D, E, N, H, R, Q, L or Y [introducing strong diversity]</p><p>at CDR2 position 3: S, T, F, G, A, W, D, E, N, H, Q, P [introducing strong diversity]</p><p>at CDR2 position 4: G, S, T, N, or D [G, S, T and N where the most frequent]</p><p>at CDR2 position 5: S, T, F, G, A, Y, D, E, N, I, H, R, Q, L, P, V, W, K or M [allowing full diversity]</p><p>at CDR2 position 6: S, T, F, G, A, Y, D, E, N, I, H, R, Q, L, P, V, W, or K [allowing strong diversity]</p><p>at CDR2 position 7: S, T, F, G, A, Y, D, E, N, I, H, R, Q, L, P, or V [allowing strong diversity]</p><p>at CDR3 for every position: S, T, F, G, A, Y, D, E, N, I, H, R, Q, L, P, V, W, K or M [introducing full diversity] CDR 3 length have been designed in order to produce 4 different subtype of hs2dAb with 9, 12, 15 or 18 residues in CDR3.</p><p>20 times, 1 µL (10 ng) of the synthesis (corresponding to 1.10<sup>10</sup> molcules) were amplified by PCR in a total volume of 50 µL using 1 µL of Phusion DNA polymerase (New England Biolabs) with an equimolar mixture of the following primers: 5’-AACATGCCATCACTCAGATTCTCG-3’ and 5’-GTTAGTCCATATTCAGTATTATCG-3’ PCR protocol consisted of an initial denaturation step at 98°C for 45 s followed by 20 cycles of 98°C for 10 s, 55°C for 30 s and 72°C for 30 s, and a final step extension at 72°C for 10 min. 7 × 150 µL of PCR were purified on 7 columns of a PCR clean-up kit (Macherey-Nagel). 55 µg of the resulting purified fragment of PCR and 80 µg of the pHEN2-ccdB-3myc phagemid were digested for 2 hr at 37°C with NcoI and NotI (New England Biolabs) in a total volume of 500 µL. A dephosphorylation step was added for the phagemid with a Calf intestinal alkaline phosphatase (Sigma-Aldrich) 30 min at 37°C. Digestions were purified on gel with respectively 4 and 6 columns of a gel extraction kit (Macherey-Nagel Sarl, France) in a final volume of 80 and 120 µL. Then, purified PCR fragment was ligated into pHEN2-ccdB-3myc, between the PelB leader signal and the pIII gene. 50 µg of phagemid and 19,2 µg of insert were ligated overnight at 16°C with 10 µL of high concentration T4 DNA ligase (New England Biolabs) in a total volume of 400 µL. Ligation was purified on 6 columns (Macherey-Nagel) with a total volume of 150 µL. The ligated DNA material was used to transform electrocompetent <italic>E. coli</italic> TG1 cells (Lucigen). 20 electroporations with 1 µL of ligation were performed according to the manufacturer’s instructions (1800 V; 10 µF; 600 Ω). Each electroporation was resuspended with 1 mL of warm 2XYT, 1% glucose medium and incubated with a shaking agitation for 1 hr at 37°C. 380 mL of 2XYT, 1%glucose was added to the suspension and plated on 430 2xYT-ampicillin agar dishes (140 mm) overnight at 37°C. Library size was calculated by plating serial dilution aliquots. The colonies were scraped from the plates with liquid 2xTY and library was stored in the presence of 30% of glycerol at −80°C with 1 mL aliquots at OD = 38,4. 3.10<sup>9</sup> individual recombinant clones were obtained.</p></sec><sec id="s30"><title>Phage display selections</title><p>Various methods outlined below were used to screen NaLi-H1 library. Three general advices can be given here: (1) In roughly 70% of the screen, specific clones were obtained. In many case, when not specific binders were recovered, we identified the antigen that was used as the principal cause of failure. It is often a good idea to insist and use an alternative target preparation and ensure its proper display during the selection phases. (2) A key step to obtain specific clones is the washing step. They should be extensive, numerous and in large volume, changing tubes several times. While it is always a good idea to start washing as quickly as possible, if the affinity of the hs2dAb obtained is too low then extended washing steps may be used in a subsequent screening to select for a low k<sub>off</sub>. (3) We usually test for binders after the second and third rounds of selection, and more rarely after a fourth round. The method used to identify binders at the end of the selection should to be as close as possible to plan usage of the recombinant antibody. If immunofluorescence is planned, it ideally should be used to identify specific binders. If western blotting is the major application, It should be the preferred method to be used.</p><p>Immunotubes (Nunc) were coated with βActin at a concentration of 20 µg/mL in PBS overnight at 4°C. Immunotubes were then rinsed with PBS and blocked for 2 hr at room temperature with 2% w/v BSA or casein in PBS. After rinsing with PBS, &gt; 10<sup>12</sup> phage particles in 2% BSA or casein were added to the immunotubes. The immunotubes were first incubated on shaker for 1 hr and then for 1 hr standing upright at room temperature. Unbound phage was washed away by rinsing the immunotubes fifteen times with PBS, 0.1% Tween 20 and five times with PBS. The bound phage fraction was eluted in 1 mL of 1 mg mL<sup>−1</sup> trypsin and inverting the tube for 10 min and then in 1 mL of 100 mM triethylamine and inverting the tube for 10 min. Triethylamine was neutralized by adding 0.5 mL 1 M Tris-HCl pH 7.4. The eluted phages were used for the infection of exponentially growing <italic>E.coli</italic> TG1.</p><p>Biotinylated antigens or SBP-antigen were diluted to obtain a 10–20 nM (1 mL final) and recovered on 50 µL streptavidin-coated magnetic beads (Dynal). As a reference, 10 nM of a 25-kDa protein like GFP represents 250 ng protein/mL (quantity used per round of selection). Efficient recovery was checked analyzing fractions of bound and unbound samples by Western blot using streptavidin-HRP or anti-AviTag antibodies. Antigen coated beads were incubated for 2 hr with the phage library (10<sup>13</sup> phages diluted in 1 mL of PBS + 0.1% Tween 20 + 2% non-fat milk). Phages were previously adsorbed on naked streptavidin-coated magnetic beads (to remove nonspecific binders). Phages bound to streptavidin-coated beads were recovered on a magnet and beads were washed 10 times (round 1) or 20 times (round 2 and 3) with PBS+Tween 0.1% on a magnet. Bound phages were eluted using triethylamine (TEA.100 mM) for 10 min and neutralized using 1 M Tris pH 7.4. The elution was done twice. <italic>E. coli</italic> (TG1) were infected with the eluted phages and plated on ampicillin containing agarose. For round 2 and round 3, only 10<sup>12</sup> phages were used as input.</p><p>Chitin binding domain from chitinase A1 (CBD) or 2strep tag (IBA) fusion of RHOA GTPase active mutant (RHOA<sub>L63</sub>) were expressed transiently during 24 hr in HEK293 cells and captured freshly after cell lysis on magnetic beads before incubation with the library phages. Chitin magnetic beads ()New England Biolabs or streptactin coated magStrep HC (IBA Gmbh, Germany) were use in a similar way as described above with streptavidin beads. A phage display panning alternating rounds on chitin beads with rounds on streptactin beads was performed for 4 rounds. From the second round of panning, a depletion step on GDP loaded wild type RHOA or N19 inactive mutant was included.</p><p>When characterizing selected antibodies, various Non Relevant (NR) hs2dAb were used as controls. The one shown here are: A non-binding clone selected against FITC (in <xref ref-type="fig" rid="fig5">Figure 5B–D</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>) and a non-binding clone selected against mCherry (in <xref ref-type="fig" rid="fig5">Figure 5A</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>)</p></sec><sec id="s31"><title>Enzyme-linked immunosorbent assay (ELISA)</title><p>Briefly, individual clones from a master plate and harboring phagemids were inoculated into 250 µL of media (2xTY, 1% glucose, 100 µg mL<sup>−1</sup> ampicillin) and grown overnight at 37°C. Ten µL of this culture were inoculated into 250 µL of fresh media for 3 hr. The culture was infected with KM13 helper phage and grown overnight in 200 µL 2xTY medium supplemented with 100 µg mL<sup>−1</sup> of ampicillin and 75 µg mL<sup>−1</sup> of kanamycin at 25°C. Supernatants from these cultures were used in phage ELISA assays. Maxisorp ELISA plate were coated with 100 µL per well of protein antigen in 100 mM carbonate buffer pH 8.6 for 2 hr at room temperature (RT) or overnight (OVN) at 4°C. Usually, 1 µg to 10 µg of antigen were used per well. A control plate was coated with BSA. Wells were rinsed once with PBS Tween 0.1% and blocked with 200 µL per well of 2% Milk + PBS Tween 0.1% for 1 hr at RT or OVN 4°C. Wells were rinsed 5 times in PBS. Twenty µL of PBS Tween 0.1% Milk and 80 µL of the phage containing supernatant were added to each well in both phage ELISA plate (antigen-coated and BSA control) for 1 hr. Wells were washed 3 times with PBS Tween 0.1% and 3 times with PBS. HRP-anti-pIII antibody (GE Healthcare) was added at 1:5.000 in PBS Tween 0.1% + 2% milk and incubated for 40 min. Wells were washed 3 times with PBS Tween 0.1% and 3 times with PBS. Reaction was developed with 100 µL of HRP substrate solution (e.g. ABTS in citrate buffer) at RT for 15 min and the optic density was read at 405 nm. RHO-GTPases ELISA were performed as previously described.</p></sec><sec id="s32"><title>Cells</title><p>All cells are regularly tested for mycoplasma contamination. The HeLa cells (RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_0030">CVCL_0030</ext-link>) used in the study has been obtained from the B. Goud lab (Institut Curie). SNP characterisation has been carried out and may be shared upon request. The H2B-GFP cell line has been obtained from the lab of E. Nigg and has been described in <xref ref-type="bibr" rid="bib47">Silljé et al. (2006)</xref>. RPE-1 immortalized by the expression of hTert (RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_4388">CVCL_4388</ext-link>) has well as the CHO cells have been obtained from the ATCC.</p></sec><sec id="s33"><title>Immunofluorescence and real-time imaging</title><p>HeLa cells were either fixed in 3% paraformaldehyde and permeabilized with PBS (plus 0.05% saponin and 0.2% BSA) or fixed and permeabilized with ice cold methanol for 4 min at −20°C. When needed, nocodazole (10 µM, 90 min) or cytochalasin D (5 µM, 60 min) were added before fixation. To activate p53 (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>), cells were irradiated using a Stratagene UV crosslinker (100 joules/m<sup>2</sup>) 24 hr before fixation. hs2dAb secreted in 600 µL 2xTY cultures (produced in 96-deep well plates) after overnight induction with 1 mM IPTG at 30°C were used undiluted without purification. hs2dAbs were co-incubated with 9E10 anti-myc monoclonal for 90 min on cells. Cells were then washed quickly twice and incubated with secondary antibodies for 30 min (Invitrogen - Thermofisher). The actin cytoskeleton was stained with Alexa594 phalloidin (1/1000). Cells were grown on coverslip and transfected with F-construct 48 hr following the manufacturer‘s recommendation. Cells were fixed in 3.7% paraformaldehyde for 7 min then rinsed twice with PBS and mounted in Mowiol. Data acquisition was carried out on a Nikon Eclipse 90i (Nikon, France)and image processing with NIS Elements v3 software or using a Leica DM6000 B microscope equipped with a CoolSnap HQ2 camera controlled by Metamorph (Molecular Device Limited, UK, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002368">SCR_002368</ext-link>)</p><p>For time-lapse imaging, Hela cells seeded on glass the day before were transfected using calcium phosphate with mCherry-Rab6 and GFP-tagged anti-cherry expression plasmids. After 24 hr, medium is replaced by pre-warmed carbonate independent Leibovitz’s medium (Invitrogen), and cells were imaged using an inverted microscope TiE (Nikon) equipped with spinning disk confocal head (PerkinElmer, Waltham, United States) and a CoolSnapHQ2 camera (Roper Scientific, France). Time-lapse images were acquired using a 63X objective and MetaMorph software (Molecular Device, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002368">SCR_002368</ext-link>) every 2 s for 4 min.</p></sec><sec id="s34"><title>Pull down</title><p>Pull down of endogenous RHO proteins loaded in active or inactive state were adapted from well-established GST-RBD pull down. HeLa cell (5.10<sup>6</sup> per immunoprecipitate) were lysed in buffer (50 mM Tris pH 7.4, 500 mM NaCl, 10 mM MgCl<sub>2</sub>, 0.5% TritonX100). Crude protein lysates Extract was loaded with 0.2 mM GTPγS or 2 mM GDP in buffer supplemented with 10 mM EDTA for 30 min at 30°C. Reaction was stopped by adding 30 mM MgCl2. For immunoprecipitation, beads bound by freshly captured CBD tag hs2dAb (4 µg) or GST-RBD (40 µg) positive control were incubated with loaded protein suspension for 45 min at 4°C. Beads were washed 3 times with 50 mM Tris-HCl. pH 7.5. 150 mM NaCl. 10 mM MgCl2. 0.1% Tween20 and denatured in 2X Laemmli reducing sample buffer, boiled for 5 min and separated on 12.5% SDS-PAGE for Western Blot analysis with anti-RHOA followed by HRP-conjugated secondary antibodies.</p><p>Co-precipitations of intrabodies (myc- tagged hs2dAb) with RHOA CA active or DN inactive mutants were performed after transient co-transfection of pCBD-RHOAQ63L or pCBD-RHOAT19N with pIb-myc in HeLa cells. After 24 hr, crude cell lysates containing CBD-RHO mutants in buffer (50 mM Tris pH 7.4. 150 mM NaCl / 10 mM MgCl2 / 0.5% TritonX100 / 10% glycerol) were incubated with chitin beads for 1 hr at 4°C. Co precipitation was revealed by RHOA antibody and myc antibody.</p></sec><sec id="s35"><title>Production and Purification of recombinant protein for affinity measurement</title><p>The monovalent hs2dAb were produced in bacterial periplasm. Briefly, XL1blue E.coli transformed with pHEN-hs2dAb-CBD-2S-6his or pHEN-Hs2dAB-6his were grown in TB-ampicillin (100 µg/mL) medium supplemented with 1% glucose in the growth phase and with 0.1% glucose during induction with 1 mM IPTG. After 16 hr of expression at 28°C, the cells were harvested and periplasmic proteins were extracted in TES (Tris 100 mM pH 8, EDTA 1 mM, Sucrose 500 mM) after osmotic shock.hs2dAb were purified in batch using IMAC affinity chromatography using Ni-NTA beads CompleteHis resin (Roche Life Science) following manufacturer indications. Elution were dialyzed in PBS 10%glycerol.</p><p>Bivalent hs2dAb were produced as fusion proteins with the Fc domain of human IgG2 as described (<xref ref-type="bibr" rid="bib32">Moutel et al 2009</xref>). hs2dAb were sub-cloned in pFuse-hIgG-Fc2 plasmid (NcoI/NotI) inframe between the interleukin-2 (IL2) secretion signal and the Fc domain. 4 days after transient transfection in CHO cells, supernatants were recovered and used directly for immunofluorescence staining of cells or for Western blot analysis. Hs2dAb-Fc were then revealed using anti-Human Fc fluorescent or HRP secondary antibodies (Jakson ImmunoResearch Laboratories, West Grove, United States).</p><p>GST-GFP or GST-mCherry were expressed in the cytosol by overnight induction in 1 liter of <italic>E.coli</italic> BL21 cells by addition of 100 μM IPTG. After centrifugation and freezing, the bacterial pellet was resuspended in 50 mM Tris-HCl, pH 8.5, 150 mM NaCl, 5 mM MgCl2, 1% Triton X-100, 10 mM dithiothreitol, 0.1 mg/ml DNase I, and protease inhibitors (Sigma-Aldrich). After centrifugation, the supernatant fraction was bound to 500 μl of pre-washed glutathione-Sepharose beads and purified in batch according to manufacturer instructions (GE Healthcare).</p><p>RHOA CA or DN mutants as well as RAC1 CA tagged with the twin Streptag II (IBA) were expressed in the cytosol of BL21 Star (DE3) pRARE <italic>E.coli</italic> cells from a pET vector and purified in the same buffer as GST-GFP but on the streptactin resin (IBA) according to manufacturer instructions.</p></sec></sec></boxed-text></app></app-group></back><sub-article article-type="article-commentary" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.16228.024</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Akhmanova</surname><given-names>Anna</given-names></name><role>Reviewing editor</role><aff id="aff10"><institution>Utrecht University</institution>, <country>Netherlands</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;NaLi-H1: A universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies&quot; for consideration by <italic>eLife</italic>. Your article has been favorably evaluated by Sean Morrison (Senior editor) and four reviewers, one of whom is a member of our Board of Reviewing Editors. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>This paper describing the generation of a synthetic nanobody library with an optimized humanized scaffold, illustrates its usefulness by showing examples of successful selection of antibodies against different antigens, including conformation-specific nanobodies, and demonstrates the use of some of these antibodies as intrabodies for protein detection and degradation. Previously, immunization of Camelids was necessary to isolate functional nanobodies. With the NaLi-H1 library this immunization step is removed and the screening is entirely performed in vitro, where at each step the conditions can be controlled and manipulated. This has several advantages as no animal experimentation is needed, and binders to highly conserved or toxic antigens can be isolated. The provided data suggest that the library will be a useful and versatile tool for selection of various nanobodies. Some of the described antibodies, such as the conformation-specific nanobody against active Rho, will be directly useful for the cell-biological community.</p><p>Essential revisions:</p><p>1) The library is assessed for diversity by sequencing, but not at all for functionality in terms of nanobody expression, folding and solubility. Given that the library only partially attempts to mimic natural diversity, reducing the levels of hydrophobic amino acids, there is a danger that attempts to improve upon nature may lead to increased aggregation/poor folding etc. Consequently, it would be important to assess the levels of functional expression of 24-48 random clones picked from the library. This could be done by assessing the levels of soluble expression levels, or preferably, using protein A (if protein A binds to the scaffold, given that it is VH3-like) to assess the percentage of protein A binding clones – which would provide an assessment of correct folding.</p><p>2) The staining of endogenous proteins with and without knockouts mediated by siRNA or Crispr-CAS9 should be demonstrated for the original anti-lamin nanobodies using the difficult scaffolds, as well as subsequently selected nanobodies. This will show first that the nanobodies are functional against natural proteins at natural levels, and second that there is no off-target binding (if knockout eliminates staining). Furthermore, functional positive control antibodies should also be included as comparisons.</p><p>3) Wherever the phrase &quot;data not shown&quot; is used, either the data should be shown (in the supplementary), or the phrase should be eliminated. Supplementary files attached to primary figures allow all data to be shown.</p><p>4) Where western blots are shown (e.g. <xref ref-type="fig" rid="fig3">Figure 3B</xref>) show the whole blot, not just that portion { ± } 5KDa around the expected target size.</p><p>5) During the description of the library the authors mention () that the purified <italic>sdAb<sup>D10</sup></italic> shows stability after heat treatment. They support this observation in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> panel B. One of the advantages of nanobody is their heat stability so the heat-purification experiment at 70 °C is not sufficient to support the claim that such scaffold is a better &quot;heat-resistant&quot; nanobody. This claim should be better supported or removed.</p><p>6) Please explain in a bit more detail how the diversity in the CDR3 was introduced, especially in the Materials and methods section.</p><p>7).Since this publication is mainly supposed to be a method-based, resource paper, it would greatly benefit from an extended description of a general protocol outline for the isolation of binders (starting from the preparation of the antigen, to the phage display and to the final screening method, with a few tips and tricks at the crucial steps). Researchers that want to use the NaLi-H1 library could use this as a starting point.</p><p>8) The authors present the success stories, but it would be good to know what percentage of attempted antibody screens was not successful.</p><p>9) Please make sure that a proper disclaimer regarding your financial interest in the commercial distribution of the library is provided in the published version of the paper.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.16228.025</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p><italic>Essential revisions:</italic> </p><p><italic>1) The library is assessed for diversity by sequencing, but not at all for functionality in terms of nanobody expression, folding and solubility. Given that the library only partially attempts to mimic natural diversity, reducing the levels of hydrophobic amino acids, there is a danger that attempts to improve upon nature may lead to increased aggregation/poor folding etc. Consequently, it would be important to assess the levels of functional expression of 24-48 random clones picked from the library. This could be done by assessing the levels of soluble expression levels, or preferably, using protein A (if protein A binds to the scaffold, given that it is VH3-like) to assess the percentage of protein A binding clones – which would provide an assessment of correct folding.</italic> </p><p>It is a good question although not easy to solve. Assessing the folding of non-binding clones is challenging. Although the binding to Protein A and Protein L has indeed been described for some VH3 (Potter, Li and Capra.J Immunol 1996; 157:2982-2988; Rodrigo, Gruvegård and Van Alstine. Antibodies 2015, 4, 259-277), the hs2dAb scaffold cannot bind Protein A nor Protein L. We believe that the synthetic scaffold does not preserve the binding interface of some natural VH3 and mainly does not contain the residues in CDR2 that determine this interaction. Alternatively, to assess the relative folding of hs2dAb, we picked randomly 26 clones and carried out sequential ultracentrifugation. We also analyzed the behavior of a few selected clones directed against GFP, mCherry or lamin, as well as the natural anti-GFP nanobody GFP (also known as Chromobody). All the antibodies we tested were found (~100% ) in the supernatant after a 250 000 g spin. After warming at 90°C for 20 minutes, over 70% stays in the supernatant confirming strong resistance to denaturation. We now provide these data as <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>.</p><p><italic>2) The staining of endogenous proteins with and without knockouts mediated by siRNA or Crispr-CAS9 should be demonstrated for the original anti-lamin nanobodies using the difficult scaffolds, as well as subsequently selected nanobodies. This will show first that the nanobodies are functional against natural proteins at natural levels, and second that there is no off-target binding (if knockout eliminates staining). Furthermore, functional positive control antibodies should also be included as comparisons.</italic> </p><p>A similar point was raised by Reviewer #2. The specificity of the anti-Lamin antibody is quite clear as it is simply a CDR grafting from a published antibody and we obtained the same staining. However, we recognize that we should do a better job showing the specificity of some of the selected binders. We added an shRNA + UV treatment experiment for the anti-p53 (new <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). Using siRNA was more complicated for HP1 because of inter- dependence that exist between the different isoform of HP1. As it would be beyond the scope of this article to study HP1 we decided not to provide siRNA data. Instead we carried out immunofluorescence upon overexpression of the different isoforms as well as western blotting (new <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>). These experiments suggest that the selected HP1 antibody is directed against α, β and γ HP1. We also carried out nocodazole and cytochalasin D experiments to characterize better the anti-tubulin and anti-actin hs2dAb, respectively (new <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>).</p><p><italic>3) Wherever the phrase &quot;data not shown&quot; is used, either the data should be shown (in the supplementary), or the phrase should be eliminated. Supplementary files attached to primary figures allow all data to be shown.</italic> </p><p>We removed the data not shown statements. In particular, we now show control experiments for p53 and HP1 antibodies.</p><p><italic>4) Where western blots are shown (e.g. <xref ref-type="fig" rid="fig3">Figure 3B</xref>) show the whole blot, not just that portion { ± } 5KDa around the expected arget size.</italic> </p><p>We already provided the full blot when we tested our novel anti-tubulin and actin antibodies because it was important in this experiment to see the potential background. For the pull down experiments (<xref ref-type="fig" rid="fig3">Figure 3B</xref>) we thought that it would be less important because what we score is whether the protein is pulled-down or not; such an experiments could be done by dot blot with essentially the same precision. In any case, we now provide the full, un-cropped, blots as supplementary data (new <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>, new <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref>, new <xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4</xref>). Note that we performed a new set of pull-down assays (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>) because previous un-cropped blots were slightly dirty.</p><p><italic>5) During the description of the library the authors mention () that the purified sdAb<sup>D10</sup> shows stability after heat treatment. They support this observation in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> panel B. One of the advantages of nanobody is their heat stability so the heat-purification experiment at 70 °C is not sufficient to support the claim that such scaffold is a better &quot;heat-resistant&quot; nanobody. This claim should be better supported or removed.</italic> </p><p>We indeed did not test extensively heat resistance of the new scaffold. However, our conclusions were still mild (&quot;Purified <italic>sdAb<sub>D10</sub></italic> showed excellent solubility, stability after heat treatment<italic>…</italic>&quot;) but it is true that only a 70 °C treatment was used. We now have tested a 90 °C treatment and confirmed partial resistance to heat denaturation. We however clarified our conclusions by removing “heat-resistant” and we now indicate that &quot;<italic>sdAb<sub>D10</sub></italic>showed excellent solubility, stability after treatment at 70 °C and we did not observe aggregation&quot;. In the Discussion we now mention that the hs2dAb displays &quot;the hs2dAb displays partial resistance and/or refolding after treatment for 20 min at 90°C.&quot;</p><p><italic>6) Please explain in a bit more detail how the diversity in the CDR3 was introduced, especially in the Materials and methods section.</italic> </p><p>More details are now provided in the Methods section. Because we thought that it may now be too long to be included in the main text, we now summarize the methods we used for library construction in the main material and methods section and provide more data in the Appendix.</p><p><italic>7) Since this publication is mainly supposed to be a method-based, resource paper, it would greatly benefit from an extended description of a general protocol outline for the isolation of binders (starting from the preparation of the antigen, to the phage display and to the final screening method, with a few tips and tricks at the crucial steps). Researchers that want to use the NaLi-H1 library could use this as a starting point.</italic> </p><p>We used a variety of protocols in this manuscript that we outlined in the previous version. We have now added a sort of generic &quot;tips and tricks&quot; summary as an introduction to the screening methods.</p><p><italic>8) The authors present the success stories, but it would be good to know what percentage of attempted antibody screens was not successful.</italic> </p><p>This is an interesting data indeed but not simple to provide because in some case, the screen fails at first but then, tuning the conditions, it finally succeeds. Probably more than 70% of the screens eventually work. When they failed, we generally identified the antigen as being the main cause. We now indicate these points in the generic &quot;tips and tricks&quot; header (see point #7).</p><p><italic>9) Please make sure that a proper disclaimer regarding your financial interest in the commercial distribution of the library is provided in the published version of the paper.</italic> </p><p>We indicated this in the manuscript (Competing financial interests). We shall see with the editors where is the proper section to indicate this point. Looking at Instruction to Authors, we realized that it should probably be present on the first page. Also, we now indicate the WIPO number.</p></body></sub-article></article>